WO2007008072A2 - CROSS-ß STRUCTURE BINDING COMPOUNDS - Google Patents
CROSS-ß STRUCTURE BINDING COMPOUNDS Download PDFInfo
- Publication number
- WO2007008072A2 WO2007008072A2 PCT/NL2006/000364 NL2006000364W WO2007008072A2 WO 2007008072 A2 WO2007008072 A2 WO 2007008072A2 NL 2006000364 W NL2006000364 W NL 2006000364W WO 2007008072 A2 WO2007008072 A2 WO 2007008072A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cross
- binding
- protein
- compound
- tpa
- Prior art date
Links
- 0 *C(C(CCC1)(C=C)C(C=CC(*)=CC=CC(*)=CC(ON)=O)=C1C=C)=C Chemical compound *C(C(CCC1)(C=C)C(C=CC(*)=CC=CC(*)=CC(ON)=O)=C1C=C)=C 0.000 description 4
- OWNYYTZOHDIWBH-UHFFFAOYSA-N CC(C)(C)C(CC(C1(C2)C(C(O3)=O)O)OC2=O)(C3OC1=O)O Chemical compound CC(C)(C)C(CC(C1(C2)C(C(O3)=O)O)OC2=O)(C3OC1=O)O OWNYYTZOHDIWBH-UHFFFAOYSA-N 0.000 description 1
- YHSGYLQZVMGWNY-XBZDCSSOSA-N CCC(C)C(C=C)/C=C/C(C(CCC1/C(/CCC2)=C/C=C(\CC(CC3)N)/C3=C=C)C12C=C)C=C Chemical compound CCC(C)C(C=C)/C=C/C(C(CCC1/C(/CCC2)=C/C=C(\CC(CC3)N)/C3=C=C)C12C=C)C=C YHSGYLQZVMGWNY-XBZDCSSOSA-N 0.000 description 1
- PQDMKUIBJZXKLI-HPQDKGJBSA-N CC[C@@](CCC1)([C@@H](C2)C(CC3)(C(C)=C)OC2=O)[C@@H]3C1(C(C)=C)C1=C2C1C2 Chemical compound CC[C@@](CCC1)([C@@H](C2)C(CC3)(C(C)=C)OC2=O)[C@@H]3C1(C(C)=C)C1=C2C1C2 PQDMKUIBJZXKLI-HPQDKGJBSA-N 0.000 description 1
- FNITXCDINQSLNF-JCDLPLFSSA-N COC(C([C@@H](C1)C(CC2)CN(CC3)[C@@H]1C1=C3C3=CC=CCC3N1)[C@H]2N)=O Chemical compound COC(C([C@@H](C1)C(CC2)CN(CC3)[C@@H]1C1=C3C3=CC=CCC3N1)[C@H]2N)=O FNITXCDINQSLNF-JCDLPLFSSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the field of biochemistry, biophysical chemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to a cross- ⁇ structure or cross- ⁇ structure induced conformations. Even more particular, the invention relates to compounds capable of binding to a protein comprising a cross- ⁇ structure.
- Polypeptides can refold spontaneously at the end of their life cycle, or refolding can be induced by environmental factors such as pH, glycation, oxidative stress, heat, irradiation, mechanical stress, proteolysis and so on, at least part of the polypeptide refolds and adopts the amyloid-like cross- ⁇ structure conformation. This conformation is then the signal that triggers a cascade of events that induces clearance and breakdown of the obsolete particle. When clearance is inadequate unwanted polypeptides can aggregate and form toxic structures ranging from soluble oligomers up to precipitating fibrils and amorphous plaques.
- cross- ⁇ structure conformation comprising aggregates underly various diseases, such as Alzheimer's disease, Huntington's disease, diabetes mellitus type 2, systemic amyloidoses or Creutzfeldt-Jakob's disease, depending on the underlying polypeptide that accumulates and on the part of the body where accumulation occurs.
- diseases such as Alzheimer's disease, Huntington's disease, diabetes mellitus type 2, systemic amyloidoses or Creutzfeldt-Jakob's disease, depending on the underlying polypeptide that accumulates and on the part of the body where accumulation occurs.
- cross- ⁇ structure comprising proteins can activate tPA and FXII, thereby initiating the fibrinolytic system and the contact system of hemostasis.
- the cross- ⁇ structure conformation may induce coagulation, platelet aggregation and blood clotting via direct platelet activation and/or the release of tissue factor (Tf) by activated endothelial cells (described in more detail in a co- pending patent application).
- Tf tissue factor
- the complement system is another example of a proteolytic cascade that is activated by cross- ⁇ structure conformation.
- This system can be activated by the amyloid- ⁇ peptide associated with Alzheimer's Disease or by zirconium or aluminum or titanium. The latter being compounds that can induce cross- ⁇ structure conformation in proteins.
- the innate and adaptive immune systems are yet another example. Amyloid- ⁇ activates the innate and adaptive immune response 2 .
- ⁇ 2- glycoprotein I is an auto-immune antigen only upon contact with a negatively charged lipid surface, such as cardiolipin 3 .
- cardiolipin induces cross- ⁇ structure conformation in ⁇ 2-glycoprotein I (described in more detail in a co-pending patent application).
- ligands for Toll-like receptors that are implicated in the regulation of immunity induce cross- ⁇ structure conformation in proteins. These ligands include lipopolysaccharide and CpG oligodeoxynucleotides (ODN) (described in more detail in a co-pending patent application).
- FXII can be activated by negatively charged agents. For example, when blood is drawn into a glass tube it rapidly clots, due to activation of FXII. However, when the tube is made of plastic clotting is delayed. This mechanism of this contact system of coagulation is termed the intrinsic pathway because all clotting factors are present in plasma; in contrast to the extrinsic pathway, which requires the presence of tissue factor on the surface of cells, that is not exposed to. the circulation during homeostasis. Interestingly, the nature of the FXII activator in vivo is still unknown. We now found that cross- ⁇ structure, that is formed when globular proteins unfold due to any denaturing trigger, is a trigger for FXII and contact activation.
- tPA amyloid binding reagents Congo Red, ThT, recombinant finger domains of tPA, FXII, HGFA and fibronectin, or full-length tPA, FXII, HGFA, fibronectin, serum amyloid P component (SAP), anti-cross- ⁇ structure antibodies and/or a soluble fragment of receptor for advanced glycation endproducts (sRAGE) inhibit activation of FXII induced by DXS500k, kaolin, any other activating surface, or by denatured polypeptides comprising the cross- ⁇ structure conformation.
- tPA is a serine protease involved in fibrin clot lysis.
- tPA stimulates activation of plasminogen into plasmin.
- Fibrin serves as an efficient cofactor in stimulating tPA mediated plasmin formation.
- fibrin and fibrin fragments a large number of other proteins or protein fragments have been found that stimulate tPA activity, though that exhibit no apparent amino-acid sequence homology. Therefore, the anticipated common structural basis underlying the acquired tPA binding remained elusive.
- amyloid-like cross- ⁇ structure the structural element found in amyloid deposits in diseases such as Alzheimer's disease, is a prerequisite and the common denominator in tPA-binding ligands 1 - 4 .
- FXII shows close homology with tPA and is known to be activated by amyloid- ⁇ (A ⁇ ) and by bacteria with an amyloid core 5 .
- the domain structure of FXII includes, like tPA, a finger domain and its sequence shows the closest homologies with tPA.
- FXII also binds fibrin (Sanchez et al. 2003, ISTH XIX Congress; surface deposited fibrin activates FXII and the intrinsic coagulation pathway) and FXII can also, like tPA, mediate the conversion of plasminogen to plasmin 6 .
- FXII like tPA, is activated by polypeptides with amyloid-like cross- ⁇ structure conformation in general.
- cross- ⁇ structure binding compounds capable of binding to a protein comprising a cross- ⁇ structure, amongst others cross- ⁇ structure binding compounds.
- Such compounds are not only useful to be able to better understand cross- ⁇ structures, but are also very useful in respect of understanding the refolding from a native state, assembly and toxicity and are also useful for the development of diagnostic and therapeutic agents or useful as component of a diagnostic or therapeutic agent.
- the goal of the present invention is to provide methods for selecting or obtaining a cross- ⁇ structure binding compound and methods for selecting or obtaining a compound capable of binding to a cross- ⁇ structure induced conformation or capable of binding a protein comprising a cross- ⁇ structure or capable of binding selectively to a certain protein with cross- ⁇ structure and not to other proteins with cross- ⁇ structure conformation. Moreover, the invention also provides uses of such compounds.
- the invention provides a method for selecting a compound capable of binding to a cross- ⁇ structure in a protein, comprising - contacting said compound with a first protein comprising a cross- ⁇ structure and allowing said compound and said protein to interact
- a cross- ⁇ structure is implemented as a part of a protein or peptide, or a part of an assembly of peptides and/or proteins, which comprises an ordered group of ⁇ -strands; typically a group of ⁇ -strands arranged in a ⁇ -sheet, in particular a group of stacked or layered ⁇ -sheets, also referred to as "amyloid".
- a typical form of stacked ⁇ -sheets is in a fibril-like structure in which the ⁇ - sheets may be stacked in either the direction of the axis of the fibril or perpendicular to the direction of the axis of the fibril.
- peptide is intended to include oligopeptides as well as polypeptides
- protein includes proteins with and without post-translational modifications, such as glycosylation. It also includes lipoproteins and complexes comprising proteins, such as protein-nucleic acid complexes (RNA and/or DNA), membrane-protein complexes, etc.
- a ⁇ -sheet is a secondary structural element in a peptide and/or protein.
- a cross- ⁇ structure comprises a tertiary or quaternary structural element in a peptide and/or protein and can be formed upon for example denaturation, proteolysis, chemical modification, multimerization or unfolding of proteins. Said cross- ⁇ structure is generally absent in non-altered globular proteins.
- Said cross- ⁇ structure is in general composed of stacked ⁇ -sheets.
- the individual ⁇ -strands run either perpendicular to the long axis of a fibril, or the ⁇ -strands run in parallel to the long axis of a fibril.
- the direction of the stacking of the ⁇ -sheets in cross- ⁇ structures is perpendicular to the long axis of the fibril 1 .
- a compound binds to a cross- ⁇ structure in a protein
- such a determined cross- ⁇ structure binding compound can further be used in the detection of other proteins that comprise a cross- ⁇ structure.
- the proteins that are detected by such a method are also included by the term cross- ⁇ binding structure.
- cross- ⁇ structure cross- ⁇ structure conformation
- cross- ⁇ conformation cross- ⁇ conformation
- the hexapeptide FP6 can form oligomers consisting of up to 15 peptide molecules, with cross- ⁇ structure conformation.
- These data provide insight in the diverse nature of the cross- ⁇ structure fold.
- the cross- ⁇ structure fold also referred to as ⁇ - pleated sheets, cross- ⁇ sheets or cross- ⁇ spine, is an ensemble of structures.
- Polypeptides differing in amino-acid sequence or length, or a polypeptide treated in different ways, may appear with cross- ⁇ structures that differ from each other to some extent.
- the inter- ⁇ -sheet distance within a cross- ⁇ structure may vary with amino-acid sequence, peptide length, and conditions leading to the formation of a cross- ⁇ structure.
- first protein comprising a cross- ⁇ structure includes a solution comprising a single type of protein or a solution comprising a set of different proteins. It is not necessary that all proteins in said solution comprise a cross- ⁇ structure. It is sufficient that only a part of said proteins comprise a cross- ⁇ structure.
- first protein comprising a cross : ⁇ structure also includes the situation wherein a protein is attached to the exterior a cell or wherein said protein is part of a (cell)matrix or part of a tissue. Said term further includes immobilized protein in general and more specific protein immobilized on a solid surface such as an ELISA well or a bead. Moreover, said protein also includes a fragment or an equivalent of a full- length/complete protein.
- said fragment or equivalent comprises a cross- ⁇ structure.
- Methods to determine whether a protein comprises a cross- ⁇ structure conformation are available to the skilled person. Examples of such methods include, but are not limited to staining with Congo red, Thioflavin S (ThS) or Thioflavin T (ThT), an ELISA binding assay using tPA or a functional fragment thereof, or an enzymatic assay such as a tPA activation assay, a factor XII activation assay or a X-ray fiber diffraction analysis. If it is determined or known that a certain protein or protein solution does not comprise or does not comprise sufficient cross- ⁇ structures the cross- ⁇ structure content in said protein or protein solution can be increased.
- Examples for the induction of a cross- ⁇ structure in a protein are provided in the experimental part herein and include factors such as those that involve changes in pH, glycation, oxidative stress, oxidation, alkylation, temperature and so on.
- a cross- ⁇ structure is induced in a protein by irradiation, mechanical stress, sonication, proteolysis, contact with or the addition of a denaturing compound, such as kaolin, dextran sulphate or an adjuvant, such as CpG-ODN or negatively charged phospholipids, including cardiolipin and so on.
- a method according to the invention further optionally comprises the induction of a cross- ⁇ structure in a first protein to induce or increase the amount of cross- ⁇ structure by subjecting said protein to a treatment that induces or increases the cross- ⁇ structure content.
- said step is performed before the step of contacting said compound with a first protein comprising a cross- ⁇ structure and allowing said compound and said protein to interact.
- the step of contacting said compound with (possible) cross- ⁇ structure binding capacity with a first protein comprising a cross- ⁇ structure can be performed in different ways. It is for example possible to contact a solution comprising a possible cross- ⁇ structure binding compound with a solution comprising a protein comprising a cross- ⁇ structure. It is also possible to coat a carrier (for example a tube or a well of an ELISA plate) with said possible cross- ⁇ structure binding compound and add a solution comprising a protein comprising a cross- ⁇ structure to said coated carrier. Or the other way around, in which a protein comprising a cross- ⁇ structure is used to coat a carrier. Methods to perform coating of a carrier are well known and will therefore not be discussed in more detail.
- cross- ⁇ structure binding compound and a protein comprising a cross- ⁇ structure are contacted, they are allowed to incubate/interact a sufficient amount of time to establish binding to each other.
- the conditions for said binding are adjusted to be as optimal as possible for each situation. For example, changes of the pH, amount of salt, temperature, concentration and so on are introduced if this is considered relevant/suitable.
- the invention thus provides a method for selecting a compound capable of binding to a cross- ⁇ structure in a protein, said method further comprises at least one and preferably more than one (for example 2 or 3) washing steps to allow for separation of bound and unbound molecules. Moreover, even if no immobilisation of the possible cross- ⁇ structure binding compound or a protein comprising a cross- ⁇ structure is performed, separation of unbound and bound material is still possible. In such a case use is for example made of a tagged possible cross- ⁇ structure binding compound.
- Said tagged possible cross- ⁇ structure binding compound is contacted with a protein comprising a cross- ⁇ structure. After allowing binding between the two, use is made of a counterpart of said tag.
- suitable tags and counterparts are the His-tag and Ni 2+ -NTA or biotin and streptavidin or gluthathione S-transferase (GST) and glutathion or maltose binding protein and anti-maltose binding protein antibody or GST and anti-GST antibody.
- GST gluthathione S-transferase
- Specific antibodies directed to the possible cross- ⁇ structure binding compound are also useful in this respect.
- the material After for example contacting a His-tagged possible cross- ⁇ structure binding compound with a first protein comprising a cross- ⁇ structure, the material is contacted with Ni 2+ -NTA (immobilised) beads and hence bound and unbound protein is subsequently separated.
- the activation of tPA, or a functional equivalent thereof, factor XII or a functional equivalent thereof or a tPA or FXII-related protease or functional equivalent thereof is part of a method according to the invention to select said compound with cross- ⁇ structure binding capacity.
- the invention provides a method for selecting a compound capable of binding to a protein with cross- ⁇ structure, comprising
- determining whether said compound at least in part binds to said cross- ⁇ structure - selecting the compound that at least in part binds to said cross- ⁇ structure, wherein said determining step is an (enzymatic, preferably competitive) assay to determine the tPA-activating or factor XII-activating ability of said first protein in the presence of said compound. Absence or decreased presence of tPA or FXII activating ability shows that said compound is capable of binding a cross- ⁇ structure; said binding results ate least in partly blocking the availability of cross- ⁇ structures to tPA or FXII.
- the invention provides a method wherein at least one of said determining steps is performed with an enzymatic assay.
- an enzymatic assay comprises the use of tPA and plasminogen and plasmin substrate, preferably S-2251 (Chromogenix Spa, Milan, Italy), in a suitable buffer, preferably the buffer is HBS (10 mM HEPES, 4 mM KCl, 137 mM NaCl, pH 7.3).
- a suitable buffer preferably the buffer is HBS (10 mM HEPES, 4 mM KCl, 137 mM NaCl, pH 7.3).
- Such an assay further comprises a standard curve with a control with cross- ⁇ structure conformation and titration curve with a sample before and after a treatment/exposure to a putatively denaturing condition.
- FXII with activated FXII substrate, preferably S-2222 or S-2302 in a suitable buffer; preferably, the buffer contains 50 mM, 1 mM EDTA, 0.001% v/v Triton-XlOO.
- FXII with prekallikrein and high molecular weight kininogen and either substrate Chromozym-PK for kallikrein or a substrate for activated FXII in a suitable buffer; preferably HBS.
- Standard curves with known cross- ⁇ structure rich activators of FXII preferably DXS ⁇ OOk or kaolin with a protein; preferably the protein is endostatin or albumin; preferably with glycated haemoglobin, A ⁇ , amyloid fibrin peptide NH 2 - 148KRLEVDIDIGIRS 160-COOH with K157G mutation.
- a possible/suspected cross- ⁇ structure binding compounds binds (or at least binds in part) to a protein comprising a cross- ⁇ structure.
- Another way to determine whether said possible cross- ⁇ structure binding compound at least in part binds a protein comprising a cross- ⁇ structure is via a competition assay wherein said competition assay is performed with a compound of which it is known or of which it is established (for example with a method according of the invention) to have cross- ⁇ structure binding capabilities.
- the invention provides a method for selecting a compound capable of binding to a cross- ⁇ structure in a protein, comprising
- said determining step is a competition assay between said compound, a first protein comprising a cross- ⁇ structure and at least one molecule selected from Table 1 or 2 or 3.
- an enzymatic competition assay is performed.
- Yet another way to determine whether said possible cross- ⁇ structure binding compound at least in part binds a protein comprising a cross- ⁇ structure is via a competition assay wherein said competition assay is performed with a compound of which it is known or of which it is established (for example with a method according of the invention) to have cross- ⁇ structure binding capabilities.
- the invention provides a method for selecting a compound capable of binding to a cross- ⁇ structure in a protein, comprising
- said determining step is a competition tPA and/or factor XII activation assay.
- the compounds listed in Table 1 and the proteins listed in Table 2 all bind to polypeptides with a non-native fold.
- this non-native fold has been designated as protein aggregates, amyloid, ⁇ -fibrils, amyloid oligomers, cross- ⁇ conformation, cross- ⁇ structure, cross- ⁇ spine, denatured protein, cross- ⁇ sheet, ⁇ -structure rich aggregates, infective aggregating form of a protein, unfolded protein, tangles, amyloid-like fold/conformation, (amyloid) plaques and other.
- the common theme amongst all polypeptides with a non-native fold, that are ligands for one or more of the compounds listed in Table 1 and 2 is the presence of a cross- ⁇ structure conformation.
- any compound or protein related to the ones listed in Table 1 and 2 are covered by the claims.
- point mutants, fragments, recombinantly produced combinations of cross- ⁇ structure binding domains and deletion- and insertion mutants are part of the set of compounds as long as they are capable of binding to a cross- ⁇ structure (i.e. as long as they are functional equivalents).
- any newly discovered small molecule or protein that exhibits affinity for the cross- ⁇ structure fold can in principle be used in any one of the methods and applications disclosed herein.
- the compounds listed in Table 3 are also considered to be part of the 'Cross- ⁇ structure pathway', and this is based on literature data that indicates interactions of the listed molecules with compounds that likely comprise the cross- ⁇ structure but that have not been disclosed as such.
- scavenger receptor MARCO binds to acetylated low-density lipoprotein and to bacteria.
- protein modifications such as oxidation and glycation introduce the cross- ⁇ structure in proteins 1 and we pointed to a role for the amyloid core structures of bacteria in the interactions with a host 5 .
- a competition assay based on the use of at least two or more than 2 of the above-mentioned compounds is also part of the invention, i.e. any combination of the compounds mentioned in Table 1 or 2 or 3 are also included herein.
- the compound of which it has been established that it at least binds to a cross- ⁇ structure of a protein is selected as a cross- ⁇ structure binding compound. Uses of such a compound will be discussed in more detail at a later point.
- the above outlined method is also used to select a binding compound that does not bind to the cross- ⁇ structure itself but to an other structure in a protein which other structure is only present in a protein that comprises a cross- ⁇ structure and which other structure is absent if said protein does not comprise a cross- ⁇ structure.
- Such other structure is further referred to as a cross- ⁇ structure induced conformation.
- the invention also provides a method for selecting a compound capable of binding to a cross- ⁇ structure induced conformation in a protein comprising a cross- ⁇ structure, comprising
- the contacting step is performed, mutadis mutandis, as described above for a method for selecting a compound capable of binding to a cross- ⁇ structure in a protein. Separation of bound and unbound molecules and induction of a cross- ⁇ structure in a first protein are also optional steps. In this method, a competition assay as described earlier is used to confirm that binding does not occur at the cross- ⁇ structure.
- a cross- ⁇ structure induced conformation binding compound obtainable with such a method is also part of the invention as well as uses of such a cross- ⁇ structure induced conformation binding compound.
- the invention also provides a bi-specific cross- ⁇ structure binding compound obtainable with a method according to the invention.
- bi-specific includes a molecule capable of binding to a cross- ⁇ structure of a protein as well as capable of binding to any other sequence present in said protein.
- the first protein comprising a cross- ⁇ structure is for example a protein in solution, preferably obtained from an organism, preferably of an organism suffering from a protein misfolding disease/conforr ⁇ ational disease/amyloidosis, and even more preferably said first protein comprising a cross- ⁇ structure is part of or obtained from a mammalian sample.
- useful samples include but are not limited to a body fluid (for example blood or lymph fluid, or cerebrospinal fluid or a part derived thereof (for example plasma)) or samples from tissues or cells which samples are optionally homogenized. It is clear for a person skilled in the art that said protein or a set of proteins can be directly applied in a method of the invention but the nature, i.e.
- amino acid composition, of said protein or set of proteins can also be identified by proteomics, including mass spectrometry. Subsequently said protein can be chemically synthesized or recombinantly expressed in vitro or in any cell, cell-based culture or organism and used for one of the embodiments of the present invention.
- the compound binding a protein comprising cross- ⁇ structure can be of diverse nature; it is for example a protein (for example an antibody or a functional fragment and/or a functional equivalent thereof), or a (small) chemical compound.
- said compound is derived from a library, preferably from a recombinant protein library or a small compound library or an antibody library or from a phage display library or from the B- cells of an immunized animal or a hybridoma collection or a quadridoma collection.
- a method according to the invention is suitable for large- scale or high-throughput screening.
- said first protein comprising a cross- ⁇ structure is optionally immobilized on a carrier.
- said first protein comprising a cross- ⁇ structure is provided with a label to, for example, facilitate identification.
- suitable labels are Universal Linkage System (ULSTM), maltose binding protein, glutathione S-transferase (GST), secreted human placental alkaline phosphatase (SEAP), His-tag, biotin, green fluorescent protein, (horse raddish) peroxidase, FLAG, myc, VSV. Immobilization and labelling of the cross- ⁇ structure binding compound is also possible.
- the invention provides a method for selecting a compound capable of binding a protein comprising a cross- ⁇ structure conformation comprising
- selecting the compound that at least in part binds to said protein comprising a cross- ⁇ structure further comprising performing a subtraction or inhibition assay with a second protein comprising a cross- ⁇ structure and selecting the compound that specifically binds to said first protein.
- selecting the compound that at least in part binds to said compound with cross- ⁇ structure further comprising performing binding assays with a series of different compounds comprising a cross- ⁇ structure and selecting the compound that specifically binds to said first protein.
- a cross- ⁇ structure comprising protein binding compound specific for said first compound is selected.
- multiple second proteins are tested to improve/establish the selectivity of said cross- ⁇ structure binding compound for said first protein.
- Such a specific compound is extremely useful for diagnostic and therapeutic application and will be discussed in more detail below.
- a cross- ⁇ structure binding compound or a cross- ⁇ structure induced conformation binding compound or a bi-specific binding compound obtainable according to a method of the invention is also included herein.
- Some useful applications of such a binding molecules are described and include, but are not limited to, detecting the presence of cross- ⁇ structure comprising proteins, inhibition of the formation of cross- ⁇ structure conformation, inhibition of the formation of amyloid fibrils, modulating cross- ⁇ structures induced toxicity and removal of cross- ⁇ structure containing molecules from any given sample or from the circulation of a mammal.
- said compound is coupled to a dialysis device that facilitates the removal of cross- ⁇ structure comprising proteins from any given sample or the circulation of a mammal.
- Such a sample can, for example, be a solution containing proteins, preferably purified proteins, more preferably proteins that are produced recombinantly, and even more preferably proteins that are prepared for use as therapeutics for the treatment of a mammal.
- a cross- ⁇ structure binding compound or a cross- ⁇ structure induced conformation binding compound obtainable according to a method of the invention provides methods for the detection or treatment of diseases associated with the formation of cross- ⁇ structure, such as, but not limited to, amyloidosis and include Alzheimer's disease (AD), light-chain amyloidosis, type II diabetes and spongiform encephalopathies.
- AD Alzheimer's disease
- light-chain amyloidosis type II diabetes
- spongiform encephalopathies s.
- a cross- ⁇ structure binding compound or a cross- ⁇ structure induced conformation binding compound obtainable according to a method of the invention is useful in methods to detect a compound with cross- ⁇ structure.
- a binding compound is bound or affixed to a solid surface, preferably a microtiter plate or preferably a chip of a surface plasmon resonance apparatus.
- the solid surfaces useful in this embodiment would be known to one of skill in the art.
- a solid surface is a bead, a column, a plastic or polymer dish, a plastic or polymer plate, a microscope slide, a nylon membrane, etc. (After blocking) the surface is incubated with a sample.
- bound molecules comprising the cross- ⁇ structure are subsequently detected using a second cross- ⁇ structure binding compound, preferably an anti-cross- ⁇ structure antibody or a molecule containing a finger module.
- the second cross- ⁇ structure compound is bound to a label, preferably an enzyme, such as peroxidase.
- the detectable label may also be a fluorescent label, biotin, digoxigenin, a His-tag, a SEAP tag, a Myc tag, a VSV tag, an MPB tag, a GST tag, a radioactive atom, a paramagnetic ion, or a chemiluminescent label.
- a detectable marker substance preferably radiolabeled with 125 I or biotin to provide reagents useful in detection and quantification of compound or its receptor bearing cells or its derivatives in solid tissue and fluid samples such as blood, cerebral spinal fluid, urine or other.
- samples may also include serum used for tissue culture or medium used for tissue culture.
- the solid surface can be microspheres for, for example, agglutination tests.
- a cross- ⁇ structure binding compound or a cross- structure induced conformation binding compound is used to stain tissue samples.
- the compound is fused to a protein or peptide suitable for detection, such as GST.
- the compound is coupled directly to a convenient label.
- the detectable label may be a fluorescent label, a biotin, a digoxigenin, a radioactive atom, a paramagnetic ion, and a chemiluminescent label. It may also be labelled by covalent means such as chemical, enzymatic or other appropriate means with a moiety such as an enzyme or radioisotope. Portions of the above mentioned compounds of the invention may be labelled by association with a detectable marker substance (e.
- radiolabeled with 125 I 99m Tc, 131 I, chelated radiolabels, or biotin to provide reagents useful in detection and quantification of compound or its receptor bearing cells or its derivatives in solid tissue and fluid samples such as blood or cerebral spinal fluid or urine.
- the cross- ⁇ structure binding compound or the cross- ⁇ structure induced conformation binding compound is incubated with the sample and after washing visualized with antibodies directed against the fused protein or polypeptide, preferably GST.
- the above sample is obtained form tissue from patients with or expected to suffer from a conformational disease.
- the tissue is derived from animals or from cells cultured in vitro.
- a cross- ⁇ structure binding compound or a cross- ⁇ structure induced conformation binding compound obtainable according to a method of the invention is also useful as part of a new diagnostic tool. Such use is particular useful for diagnostic identification of conformational diseases or diseases associated with amyloid formation, like AD or diabetes. It is clear that this diagnostic use is also useful for other diseases and processes which involve cross- ⁇ structure formation, like all amyloidosis type diseases, atherosclerosis, diabetes, bleeding, thrombosis, renal failure with kidney dialysis regime, multiple myeloma, lymphoma or sepsis and complications thereof such as disseminiated intravascular coagulation (DIC).
- DIC disseminiated intravascular coagulation
- cross- ⁇ structure binding compound For example, one can use the obtained cross- ⁇ structure binding compound and provide it with a label, such as, but not limited to a radiolabel, such as 125 I or a fluorescent label.
- a label such as, but not limited to a radiolabel, such as 125 I or a fluorescent label.
- This labelled cross- ⁇ structure binding compound can then be used either in vitro or in vivo for the detection of cross- ⁇ structure comprising proteins, hence for determining the presence of apoptotic cells, a plaque, a protein deposition, an occlusion in the circulation, a thrombus or a lesion or a necrotic area involved in a conformational disease.
- this invention provides a method for inhibiting the formation of protein aggregation and the formation of amyloid fibrils or to modulate cross- ⁇ structure induced effects, including, cell toxicity, inflammatory responses, immunogenicity, fibrinolytic activity or thrombogenicity, including activation of platelets.
- the inhibition of protein aggregation and/or amyloid formation preferably has the consequence of decreasing the load of protein aggregates and/or fibrils. Inhibition is not restricted to amyloid fibrils, and besides protein aggregates includes any other appearance of the cross- ⁇ structure fold, for example also in soluble oligomers.
- the inhibition of cross- ⁇ structure comprising oligomers, protein aggregation, amyloid fibril formation or modulating cross- ⁇ structure mediated cell toxicity, inflammation, immunogenicity, fibrinolytic activity or thrombogenicity, including platelet activation may also have the consequence of modulating cell death.
- the cell can be any cell, but preferably is a neuronal cell, an endothelial cell, a platelet, a renal cell, a liver cell, a macrophage or a tumor cell.
- the cell can be a human cell or a cell from any other organism.
- the cell may typically be present in a subject.
- the subject to which the cross- ⁇ structure binding compound is administered may be a mammal and preferably a human.
- the subject may be suffering from amyloidoses, from another conformational disease, from prion disease, from chronic renal failure and/or dialysis related amyloidosis, from atherosclerosis, from cardiovascular disease, from autoimmune disease, from multi organ dysfunction syndrome (MODS) or the subject may be obese.
- amyloidoses from another conformational disease, from prion disease, from chronic renal failure and/or dialysis related amyloidosis, from atherosclerosis, from cardiovascular disease, from autoimmune disease, from multi organ dysfunction syndrome (MODS) or the subject may be obese.
- the diseases which may be treated or prevented with the methods of the present invention include but are not limited to diabetes, Alzheimer's disease, senility, renal failure, hyperlipidemea atherosclerosis, neuronal cytotoxicity, Down's syndrome, dementia associated with head trauma, amyotrophic lateral sclerosis, multiple sclerosis, amyloidosis, male impotence, wound healing, periodontal disease, neuropathy, retinopathy, nephropathy or neuronal degeneration.
- a cross- ⁇ structure binding compound or a cross- ⁇ structure induced conformation binding compound obtainable by a method according to the invention may be constant or for a certain period of time.
- the compound may be delivered hourly, daily, weekly, monthly (e.g. in a time release form) or as a one-time delivery (bolus delivery).
- the delivery may also be continuous, e.g. intravenous delivery.
- the invention provides a pharmaceutical composition comprising a compound capable of binding to a protein with cross- ⁇ structure obtainable by the method according to the invention. Even more preferably, said compound is selected for its specificity, i.e.
- the invention provides use of a cross- ⁇ structure binding compound in the preparation of a medicament for the treatment of a cross- ⁇ structure related disease.
- a carrier may be used.
- the carrier may be a diluent, an aerosol, an aqueous solution, a nonaqueous solution or a solid carrier.
- This invention also provides pharmaceutical compositions including therapeutically effective amounts of a cross- ⁇ structure binding compound, together with suitable . diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
- Such compositions may be liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e. g., Tris-HCL, acetate, phosphate, carbonate, ammonium), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.
- solubilizing agents e. g., glycerol, polyethylene glycerol
- antioxidants e. g., ascorbic acid, sodium metabisulfite
- preservatives e. g., Thimerosal, benzyl alcohol, methylhydroxybenzoate, parabens, m-cresol
- bulking substances or tonicity modifiers e.
- lactose mannitol
- covalent attachment of polymers such as polyethylene glycol to the compound, in complex with metal ions, or incorporation of the compound into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, micro emulsions, micelles, unilamellar or multi lamellar vesicles, erythrocyte ghosts, or spherop lasts.
- the administration of a cross- ⁇ structure binding compound obtainable by a method according to the invention may comprise intralesional, intraperitoneal, intramuscular, subcutaneous or intravenous injection; infusion; liposor ⁇ e-mediated delivery; topical, intrathecal, gingival pocket, per rectum, intrabronchial, nasal, oral, otic or ocular delivery.
- the administration includes intrabronchial administration, anal, intrathecal administration or transdermal delivery.
- the cross- ⁇ structure binding compound may be administered hourly, daily, weekly, monthly or annually.
- the effective amount of the cross- ⁇ structure binding compound comprises from about 0.000001 mg/kg body weight to about 1000 mg/kg body weight.
- the cross- ⁇ structure binding compound obtainable with a method according to the invention may be delivered locally via a capsule which allows sustained release of the agent over a period of time.
- Controlled or sustained release compositions include formulation in lipophilic depots (e. g., fatty acids, waxes, oils).
- particulate compositions coated with polymers e. g., poloxamers or poloxamines
- the cross- ⁇ structure binding compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors.
- Other embodiments of the cross- ⁇ structure binding compound incorporate particulate forms of protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
- the effective amount of the cross- ⁇ structure binding compound preferably comprise 1 ng/kg body weight to about 1 gr/kg body weight. The actual effective amount will be based upon the size of the cross- ⁇ structure binding compound and its properties.
- the invention provides the use of a cross- ⁇ structure binding compound or a cross- ⁇ structure induced conformation binding compound for the detection and removal of compounds with cross- ⁇ structures.
- Said compound is preferably a cross- ⁇ structure binding molecule, more preferably a protein and/or a functional equivalent and/or a functional fragment thereof.
- the invention also comprises antibodies that bind proteins with cross- ⁇ structures. Examples of suitable antibodies are camel and lama antibodies.
- said protein is an antibody and/or a functional equivalent and/or a functional fragment thereof.
- the invention provides for example a therapeutic method to remove cross- ⁇ structure comprising proteins from for example the circulation, preferably via extracorporeal dialysis.
- a patient with sepsis is subjected to such use by dialysis of blood of said patient through means which are provided with for example, preferably immobilized, cross- ⁇ structure binding compounds of the invention.
- the present invention discloses a composition comprising a compound capable of binding to a cross- ⁇ structure in a protein obtainable by a method of the invention or a compound capable of binding to a cross- ⁇ structure induced in a protein.
- the invention discloses a pharmaceutical composition comprising a compound capable of binding to a cross- ⁇ structure in a protein obtainable by a method of the invention or a compound capable of binding to a cross- ⁇ structure induced in a protein.
- the invention provides a method for at least partly- removing from a solution a protein comprising a cross- ⁇ structure comprising contacting a compound capable of binding to a protein with cross- ⁇ structure obtainable by the method according to the invention with said solution and removing the resulting complex of said protein with cross- ⁇ structure and said compound from said solution.
- the invention provides the use of a compound capable of binding to a cross- ⁇ structure in a protein, said compound obtainable by a method of the invention or a compound capable of binding to a cross- ⁇ structure induced conformation in a protein, said compound obtainable by the method of any one of claims 2 to 8 for detection of a cross- ⁇ structure in a protein.
- the invention further provides a method for selecting an inhibitor that is capable of at least partly blocking the binding of a selected cross- ⁇ structure binding compound and a protein comprising a cross- ⁇ structure, comprising
- the invention Upon selection of a cross- ⁇ structure binding compound the invention further provides a method for selecting a binding molecule capable of binding to a selected cross- ⁇ structure binding compound, comprising - contacting said selected cross- ⁇ structure binding compound with a binding molecule suspected to be capable of binding to said cross- ⁇ structure binding compound and allowing said compound and binding molecule to interact
- the invention further provide use of a compound capable of binding to a cross- ⁇ structure in a protein or a compound capable of binding to a cross- ⁇ structure induced conformation in a protein obtainable by the method of the invention for diagnostics.
- Example 1 Monoclonal antibodies bind specifically to peptide and protein aggregates with amyloid-like cross- ⁇ structure conformation.
- a ⁇ and ⁇ -globulins were incubated for 72 h at 37°C or at room temperature, and afterwards stored at room temperature or at -20°C, respectively.
- FP6 and FP13 K157G were kept at room temperature.
- Hb-AGE was prepared by incubating haemoglobin (Hb, 5 mg ml" ⁇ Sigma-Aldrich, H7379) for 32 weeks at 37°C with PBS containing 1 M of glucose-6-phosphate (g6p, Sigma-Aldrich, G7250) and 0.05% m/v of NaN3.
- Presence of cross- ⁇ structure conformation in Hb-AGE was confirmed by tPA binding, circular dichroism spectropolarimetry analyses, transmission electron microscopy (TEM) imaging of fibrillar structure conformations and by Congo red fluorescence measurements (not shown).
- Presence of cross- ⁇ structure conformation in FP13 K157G was confirmed by Congo red fluorescence, ThT fluorescence, TEM imaging, X-ray diffraction analysis, tPA binding, and tPA- and factor XII activation assays.
- FP6 ⁇ -globulins and A ⁇ were analyzed with Congo red fluorescence assay, ThT fluorescence assay, tPA binding ELISA, tPA activation assay and TEM imaging (not shown).
- mice Fourty nine weeks later, the mouse was immunized with 50 ⁇ g chicken serum amyloid A in ⁇ bO-Specol. Four weeks later, the mouse was immunized with 50 ⁇ g Hb-AGE. Finally, 31 and 32 days later the mouse was boosted twice intravenously with 50 ⁇ g FP6 in PBS. Three days after the final boost, the mouse was sacrificed and the spleen was used to prepare hybridomas.
- Hybridomas were screened for production of anti-cross- ⁇ structure antibodies.
- 768 clones in 96-wells plates were screened for the presence of antibodies that bind to immobilized FP13 K157G amyloid and amyloid ⁇ -globulins.
- FP13 K157G and amyloid ⁇ -globulins were diluted together in H2O to 5 ⁇ g ml" 1 of each polypeptide.
- Microlon high-binding ELISA plates (Greiner, Bio-One GmbH, Frickenhausen, Germany) were filled with 50 ⁇ l of this solution and air-dried overnight at 37 0 C.
- FP13 K157G, Hb and ⁇ -globulins were coated onto Immobilizer plates (Exiqon, Vedbsek, Denmark). These freshly dissolved controls were coated at 20, 12.5, 50 and 50 ⁇ g ml" 1 , respectively, in PBS, for 1 h at RT while shaking.
- Greiner plates were not blocked during initial screens with 768 clones. Ten % FCS in the cell culture medium is an efficient blocker during the incubation of cell supernatant in the ELISA plates. Ten ⁇ l of PBS/1% Tween-20 was added to the wells of the Exiqon plates, before cell supernatants were added. Tween-20 at a concentration of 0.1% is an effective instant blocker for Immobilizer plates. Hundred ⁇ l of the hybridoma supernatants was transferred to the plates. Culture medium was used as negative control. Signals were calculated as multiples of the signals obtained when fresh culture medium with 10% FCS was incubated on the various immobilized antigens and controls. Signals were considered positive when exceeding 2.Ox the background values obtained with fresh culture medium.
- ⁇ -globulins with altered conformation was prepared as follows. To prepare heat-denatured ⁇ -globulins, lyophilized ⁇ -globulins were heated to 85°C.
- ⁇ -globulins was heated for five cycles in PCR cups in a PTC-200 thermal cycler (MJ Research, Inc., Waltham, MA, USA). In each cycle, ⁇ -globulins was heated from 30 to 85 0 C at a rate of 5°C/min.
- Acid- and base denatured ⁇ -globulins was prepared by adding either 60 ⁇ l 5 M HCl or 60 ⁇ l 5 M NaOH to 26 ml of 10 mg ml- 1 ⁇ - globulins in HBS (10 mM HEPES, 4 mM KCl, 137 mM NaCl, pH 7.3), followed by a 40 min. incubation at 37°C. Then, either 60 ⁇ l 5 M NaOH or 60 ⁇ l 5 M HCl was added respectively to neutralize the previously added acid or base. In a control solution, 60 ⁇ l 5 M HCl and 60 ⁇ l 5 M NaOH was pre-mixed and added to the ⁇ -globulins solution, before the 40 min.
- Oxidized forms of freshly dissolved y- globulins were obtained as follows: I. 3.1 mg mH ⁇ -globulins in PBS with 20 ⁇ M CuSO 4 , II. 1 mg ml- 1 ⁇ -globulins in PBS with 480 ⁇ M CuCl 2 , III 367 ⁇ g ml" 1 ⁇ -globulins in PBS with 480 ⁇ M CuCl 2 , and W. 367 ⁇ g ml- 1 ⁇ -globulins in PBS with 200 ⁇ M CuCl 2 .
- Amyloid ⁇ -globulins were coated onto a high-binding plate (Greiner Microlon, Bio-One GmbH, Frickenhausen, Germany), blocked with Roche blocking reagent, and overlayed with 10 times diluted hybridoma cell culture medium with a concentration series of Congo red.
- the inhibitory effect of compounds with cross- ⁇ structure conformation on binding of a monoclonal antibody to immobilized cross- ⁇ structure conformation comprising antigens was tested with an ELISA set-up.
- a limiting amount of antigen i.e. 0.5 ⁇ g ml" 1 amyloid ⁇ -globulins, was immobilized onto a Greiner high-binding plate.
- cross- ⁇ structure conformation activates components of the "Cross- ⁇ structure pathway"
- Refolding can also be induced by environmental factors such as pH, glycation, oxidative stress, heat, irradiation, mechanical stress, (proteolytic) breakdown. At least part of the polypeptide refolds and adopts the amyloid-like cross- ⁇ structure conformation. This structural motif is then the signal that triggers a cascade of events that induces clearance and breakdown of the obsolete particle. When clearing is inadequate, unwanted polypeptides can aggregate and form toxic structures ranging from soluble oligomers up to precipitating fibrils and amorphous plaques.
- Various diseases are associated with protein aggregation and amyloid formation, such as Alzheimer's disease, Huntington's disease, diabetes mellitus type 2, systemic amyloidoses or Creutzfeldt-Jakob's disease, depending on the underlying polypeptide that accumulates and on the part of the body where accumulation occurs.
- the immune system is also part of the proposed cross- ⁇ structure pathway (see patent P71713EP00).
- Cells including those of the innate immune system, such as macrophages and dendritic cells express scavenger receptors that bind proteins containing cross- ⁇ structure conformation. Together with extracellular proteases, such as tPA and factor XII, these cells act as a first defense mechanism to adequately regulate the turnover of unwanted proteins.
- a second line of defense within the cross- ⁇ structure pathway is the clearance of any particle exposing cross- ⁇ structure conformation by triggering the adaptive immune system to elicit specific antibodies to the 'foreign' structure and/or a T-cell response. Those antibodies may be raised against any sequential or structural detail of the obsolete particle, or against a combination thereof.
- the set of proteins with cross- ⁇ structure conformation that may trigger an immune response is broader than unfolded-/refolded- and aggregated self-polypeptides, and comprises, but is not restricted to, pathogens exposing coat proteins with amyloid-like structure 5 .
- a second stimulus can be provided by ligands that activate Toll-like receptors.
- ligands include CpG-ODN or lipopolysaccharide (LPS).
- LPS lipopolysaccharide
- Hybridomas were formed and their cell culture supernatants were screened for the presence of antibodies that specifically recognize an epitope that is only recognized when cross- ⁇ structure conformation is present in any polypeptide with an amino-acid composition that is unrelated to antigens used for immunization.
- Out of 768 clones six clones, 2E2, 4F4, 7Hl, 7H2, 7H9 and 8F2, were selected that show affinity for a broader range of amyloid-like aggregates other than the antigens used for immunization (Fig. 1).
- cross- ⁇ structure conformation dependent antibodies would bind epitopes that require the presence of cross- ⁇ structure conformation in one of the used antigens, thus in either A ⁇ (1-40) E22Q, or serum amyloid A, or glycated Hb.
- 7H2 binds specifically to amyloid ⁇ -globulins and base-denatured ⁇ -globulins, but not to native ⁇ -globulins, nor to the amyloid antigens used for the immunizations, i.e. A ⁇ (1-40) E22Q, Hb-AGE:32 (Fig. IG-J).
- cross- ⁇ structure conformation is part of the epitope for monoclonal antibody 7H2
- Monoclonal antibody 7H2 preferentially binds to a subset of amyloid- like aggregates of ⁇ -globulins
- 7H2 is a monoclonal antibody that specifically binds to a unique epitope in ⁇ -globulins that requires the presence of cross- ⁇ structure conformation, but only when induced by treatment at high pH, but not when induced by treatment at low pH.
- Similar inhibition studies are conducted with all six monoclonals and concentration series of tPA, K2P tPA, finger domains thereof, soluble fragment of receptor for advanced glycation endproducts, ThT, ThS, and mutual exchanged monoclonal antibodies.
- tPA concentration series of tPA
- K2P tPA K2P tPA
- finger domains thereof soluble fragment of receptor for advanced glycation endproducts
- ThT ThS
- mutual exchanged monoclonal antibodies Predicted explanation for an autoimmune response of the immunized mouse
- Antibodies with specificity for a subset of cross- ⁇ structure conformations relevance to the clinic
- Each type of specific or broad range anti-cross- ⁇ structure antibody can be tested for potential neutralizing properties in any kind of assay that serves as a model to test immunogenicity and/or toxicity and/or thrombogenicity of compounds that comprise the cross- ⁇ structure conformation, or in any other assay conducted to study the in vitro, in vivo or ex vivo pathophysiological or physiological role of amyloid.
- the role of cross- ⁇ structure conformation in fibrinogen) biology can be examined with the use of the antibodies, as well as the a role in blood platelet biology.
- anti-cross- ⁇ structure antibodies may have therapeutic value.
- monoclonal 7H2 may have beneficial effects when administered to patients suffering from (systemic) amyloidosis related to aggregation of immunoglobulins or fragments thereof.
- Example 2 Anti- ⁇ 2GPI autoantibodies derived from patients with antiphospholipid syndrome recognize ⁇ 2GPI comprising cross- ⁇ structure, but not native ⁇ 2GPI.
- Plasmin (PIm) activity was assayed as described 4 .
- Peptides and proteins that were tested for their stimulatory ability were used at 100 ⁇ g ml 4 , unless stated otherwise.
- Tissue-type plasminogen activator (tPA, Actilyse, Boehringer- Ingelheim) and plasminogen (PIg, purified form human plasma by lysine- affinity chromatography) were used at concentrations of 400 pM and 1.1 or 0.22 ⁇ M, respectively.
- Chromogenic substrate S-2251 Chromogenic substrate S-2251 (Chromogenix, Instrumentation Laboratory SpA, Milano, Italy) was used to measure PIs activity.
- Fluorescence of ThT — amyloid-like protein/peptide adducts was measured as follows. Solutions of 25 ⁇ g ml 1 of protein or peptide preparations were prepared in 50 mM glycine buffer pH 9.0 with 25 ⁇ M ThT. Fluorescence was measured at 485 nm upon excitation at 435 nm. Background signals from buffer, buffer with ThT and protein/peptide solution without ThT were subtracted from corresponding measurements with protein solution incubated with ThT. Regularly, fluorescence of A ⁇ was used as a positive control, and fluorescence of FPlO, a non-amyloid fibrin fragment 4 , and buffer was used as a negative control. Fluorescence was measured in triplicate on a Hitachi F-4500 fluorescence spectrophotometer (Hitachi, Ltd., Tokyo, Japan).
- grids were prepared according to established procedures. Samples were applied to 100-mesh copper grids with carbon coated Formvar (Merck, Germany), and subsequently washed with PBS and H2O. Grids were applied to droplets of 2% (m/v) methylcellulose with 0.4% (m/v) uranylacetate pH 4. After a 2'-minutes incubation grids were dried on a filter. Micrographs were recorded at 80 kV, at suitable magnifications on a JEM-1200EX electron microscope (JEOL, Japan).
- ⁇ 2-glycoprotein I ⁇ 2GPI Purification of ⁇ 2-glycoprotein I ⁇ 2GPI was performed according to established methods 15 - 16 .
- Recombinant human ⁇ 2GPI was made using insect cells and purified as described 15 .
- Plasma derived ⁇ 2GPI as used in a factor XII ELISA, the PIg- activation assay and in the anti-phospholipid syndrome antibody ELISA (see below) was purified from fresh human plasma as described 16 .
- ⁇ 2GPI was purified from, either fresh human plasma, or frozen plasma using an anti- ⁇ 2GPI antibody affinity column 17 .
- Binding of human factor XII from plasma (Calbiochem) or of recombinant human tPA to ⁇ 2GPI purified from human plasma, or to recombinant human ⁇ 2 GPI was tested in an ELISA. Ten ⁇ g of factor XII or tPA in PBS was coated onto wells of a Costar 2595 ELISA plate and overlayed with concentration series of ⁇ 2GPI. Binding of ⁇ 2GPI was assessed with monoclonal antibody 2B2 17 .
- Binding of factor XII to ⁇ 2GPI was also tested using immunoblotting.
- ⁇ GPI 33 ⁇ g purified either from fresh plasma or from frozen plasma loaded onto a 7.5% poly-acrylamide gel. After blotting to a nitrocellulose membrane (Schleicher & Schuell), the blot was incubated with 100Ox diluted rabbit polyclonal anti-human factor XII antibody (#233504, Calbiochem) and after washing with 300Ox diluted peroxidase-coupled swine anti-rabbit immunoglobulins (SWARPO, #P0217, DAKO, Denmark). ThT fluorescence of B 2 GPI was measured as follows.
- the anti-phospholipid syndrome is an autoimmune disease characterized by the presence of anti- ⁇ 2-glycoprotein I auto-antibodies 15 - 18 .
- Two of the major clinical concerns of the APS are the propensity of auto-antibodies to induce thrombosis and the risk for fetal resorption 19 - 20 . Little is known about the onset of the autoimmune disease. Recent work has demonstrated the need for conformational alterations in the main antigen in APS, 62-glycoprotein I
- Binding of native 62GPI to certain types of ELISA plates mimicks the exposure of the cryptic epitopes that are apparently present in APS patients 15 - 18 - 21 . It has been demonstrated that anti-62GPI autoantibodies do not bind to globular 62GPI in solution, but only when 62GPI has been immobilized to certain types of ELISA plates 15 - 18 - 21 .
- the globular (native) form of the protein is not immunogenic, but requires the addition of CL, apoptotic cells or modification by oxidation 3 - 22 " 24 .
- Recombinant ⁇ 2GPI, but not ⁇ 2GPI purified from fresh plasma stimulate tPA- mediated conversion of PIg to plasmin, as measured as the conversion of the plasmin specific chromogenic substrate S-2251 (Fig. 2A).
- tPA and factor XII bind recombinant B2GPI, but not bind to ⁇ 2GPI purified from fresh human plasma (Fig. 2B, C).
- Recombinant ⁇ 2GPI binds to factor XII with a k D of 20 nM (Fig. 2C) and to tPA with a k D of 51 nM (Fig. 2B).
- Fig. 2F shows that exposure of B 2 GPI to CL or DXS ⁇ OOk introduces an increased ThT fluorescence signal, illustrating a conformational change in 62GPI accompanied with the formation of cross- ⁇ structure conformation.
- recombinant B2GPI initially already gave a higher ThT fluorescence signal than native B2GPI purified from plasma.
- exposure of plasma B2GPI and rec. 62GPI to adjuvants/denaturants LPS or CpG-ODN also induces an increase in ThT fluorescence, which is larger with rec. 62GPI than with plasma 62GPI for both adjuvants (Fig. 2M and Fig. 4C).
- structurally altered 62GPI may be obtained by any other chemical or physical treatment, e.g. heating, pH changes, reduction-alkylation.
- a person skilled in the art is able to design and perform in vitro cellular assays and in vivo mouse models to obtain further evidence for the role of the cross- ⁇ structure conformation in autoimmunity (see below).
- inhibition studies can be conducted with any cross- ⁇ structure binding compound that may compete with antibody binding or that may prevent an immune response. Our observations indicate that cross- ⁇ structure conformation is necessary for the induction of an adaptive immune response.
- cross- ⁇ structure conformation could also be part of an epitope recognized by autoimmune antibodies. Based on our studies it is predicted that other diseases and complications in which autoantibodies are implicated are mediated by a protein comprising cross- ⁇ structure conformation. In addition to the antiphospholipid syndrome such conditions include, but are not limited to systemic lupus erythematosus (SLE), type I diabetes, red cell aplasia and the formation of inhibitory antibodies in haemophilia patients treated with factor VTII.
- SLE systemic lupus erythematosus
- type I diabetes type I diabetes
- red cell aplasia red cell aplasia
- inhibitory antibodies in haemophilia patients treated with factor VTII.
- a person skilled in the art is now able to address whether the cross- ⁇ structure is present in proteins causing autoimmune disease. For example, provided that the underlying protein is known, a skilled person can perform analysis to detect the presence of cross- ⁇ structure.
- Methods to determine whether a protein comprises a cross- ⁇ structure conformation are available to the skilled person. Examples of such methods include, but are not limited to staining with Congo red, Thioflavin S (ThS) or Thioflavin T (ThT), an ELISA binding assay using tPA or a functional fragment thereof, an ELISA using one of the compounds or proteins listed in Table 1-3, a tPA activation assay or a X- ray fiber diffraction analysis.
- Thioflavin S Thioflavin S
- Thioflavin T Thioflavin T
- Fibrin peptide FP6 adopts two distinct amyloid- like conformations Solutions of fibrin peptide FP6, NH2-IDIKIR-COOH (Peptide facility, Dutch Cancer Institute, Amsterdam, the Netherlands) were prepared in various ways. FP6 was dissolved in hexafLuoro-2-propanol and trifluoroacetic acid in a 1:1 volume ratio, at approximately 10 mg ml- 1 . Solvents were subsequently evaporated and FP6 was dissolved in H 2 O at 1 mg ml - 1 or at 10 mg ml 1 . Batches were incubated at 37°C or at 65°C, for 72h, and subsequently stored at room temperature.
- the fibrin peptide FP6, NH2-IDIKIR-COOH, has been described as the smallest fibrin fragment with tPA activating properties 27 . We were wondering whether this hexapeptide has similar structural properties as seen in non- fibrin polypeptides that activate tPA, i.e. the cross- ⁇ structure conformation 1 ' 4 . Indeed we found that FP6 has properties illustrating the presence of amyloid- like cross- ⁇ structure conformation.
- the dissolved peptide activates tPA in the chromogenic plasmin activity assay, can form fibrils and enhances Congo red fluorescence (Fig. 3A-D).
- X-ray diffraction analyzes not only showed that FP6 comprises amyloid-like structure, but in addition revealed that at one site FP6 first dissolved in organic solvents, then in H2O and incubated at 37°C or at 65°C, or directly dissolved in H2O, and at the other site FP6 dissolved directly in H2O and kept at room temperature or dissolved directly in H2O pH 2 (HCl) and incubated at 65°C, have adopted two distinct conformations with properties that resemble the cross- ⁇ structure.
- the two distinguishable structures display similar structural features within the plane of the ⁇ -sheets that builds up a cross- ⁇ structure conformation, with respect to inter ⁇ -strand distance (4.7 A) and dimension of the repeating unit in the direction of the peptide bonds.
- the X- ray diffraction experiments indicate that ⁇ -strands are oriented in an anti- parallel manner (Fig. 3E, F).
- FP6-1 and FP6-2 have two different amyloid-like conformation that both have features of the cross- ⁇ structure, that is to say, both structures are composed of layered ⁇ -sheets.
- these ⁇ -sheet layers are positioned in an alternating fashion at 9-10 A or at 12-14 A distance in both structures (Fig. 3G).
- the two structures of FP6-1 and FP6-2 are however distinct with respect to the translational shift of two adjacent ⁇ -sheets.
- subsequent layers of ⁇ -sheets are positioned right on top of each other (Fig. 3H).
- adjacent layers are shifted over 2.35 A in the direction of the inter ⁇ -strand hydrogen bond direction (typically 4.7 A) in a way that a staggered configuration is adopted (Fig. 31).
- structure 2 can be designated as an amyloid-like cross- ⁇ structure. This is based on the fact that also fibrils with structure 2 are built up by layered ⁇ - sheets, like structure 1, and based on recent information that a seven-residue peptide segment from yeast prion-like protein Sup35 adopts an amyloid-like structure similar to structure 2 (ref. 28 ). Similar to the infectious nature of mammalian prions, conversion of Sup 35 to amyloid-like fibrils is associated with transmissible infection.
- Polypeptides differing in amino-acid sequence or length, or a polypeptide treated in different ways, may appear with cross- ⁇ structures that differ from each other to some extent. This was already noticed for a long time when the varying inter ⁇ -sheets spacings are concerned.
- the interesting likelihood that every polypeptide can arrange itself in a unique cross- ⁇ structure conformation with respect to inter ⁇ -sheet spacing and/or with respect to a translational shift between adjacent ⁇ -strands, with yet common aspects seen in every amyloid-like fold opens the way to the design of therapeutics, either small molecule drugs or protein-based pharmaceuticals, that are polypeptide- and disease specific.
- a drug that specifically abolishes the pathological effects of aggregation-prone serum amyloid A (SAA) by binding to aspects of SAA that are unique to the amyloid form of the protein does not disturb tPA-mediated fibrinolysis upon binding to the cross- ⁇ structure conformation in fibrin polymers.
- Example 4 Screening of compound libraries, recombinant proteins and/or antibodies for the identification of lead compounds that interact with misfolded proteins.
- AD Alzheimer's Disease
- Hb-AGE glycated amyloid- like haemoglobin
- tissue-type plasminogen activator tPA
- tPA tissue-type plasminogen activator
- the screening technology is applicable for any protein that interacts with misfolded protein(s), such as those listed in Table 2 and Table 3.
- the human BiP gene except the signal peptide encoding region was obtained from Geneart (Germany).
- the gene was extended in a way that the transcribed protein contains a carboxy-terminal extension with amino-acid sequence KSKSKSMMAA, for purposes related to couplings to matrices.
- a BamHI restriction site was added to the 5' region, a Notl restriction site to the 3' region.
- the gene was supplied in a vector and digested with BamHI and Notl for ligation in the PABG674 expression vector of the local Expression Facility Utrecht (The Netherlands). Expression of BiP in this vector results in addition of a carboxy-terminal His-tag and a carboxy-terminal FLAG-tag.
- 2 ⁇ g of vector with BiP was transiently transfected in HEK 293E cells. Cells were allowed to grow for 4 days. Cell culture supernatant comprising BiP was used for binding studies.
- IgG Human broad spectrum immunoglobulin G (IgG) antibodies, referred to as 'intravenous Ig' (TVIg' or TgIV), 'gammaglobulin', 'intravenous immune globulin', 'intravenous immunoglobulin' or otherwise, were obtained from the local University Medical Center Utrecht Pharmacy.
- Octagam from Octapharma (Octapharma International Services N. V., Brussel, Belgium; dosage 2.5 gr. in 50 ml, was used.
- Octagam is supplied as a ready-to-use solution comprising 50 mg/ml IgIV.
- IVIg is stored at 4°C. According to the manufacturer, Octagam mainly consists of IgG's (>95%), with a minor IgA fraction ( ⁇ 5%). The distribution over the four IgG isotypes is: IgGl, 62.6%; IgG2, 30.1%; IgG3,
- alkaline phosphatase conjugated antibodies was assessed using p-nitrophenyl phosphate disodium 6*H2O (Sigma-Aldrich, St. Louis, MO, USA; Phosphatase substrate catalogue number 104), and binding of peroxidase-conjugated antibodies was assessed using 1,2-phenylenediamine ('OPD', Merck, Darmstadt, Germany; catalogue number 1.07243.0050).
- Antigens used in IgIV binding ELISA's were bovine serum albumin (BSA, fraction V, catalogue number A-7906, initial fractionation by heat shock, purity > 98% (electrophoresis), remainder mostly globulins, Sigma-Aldrich, St. Louis, MO, USA), human haemoglobin (Hb, Sigma-Aldrich; catalogue number H7379), and their advanced glycated end products-modified counterparts BSA- AGE and Hb-AGE (see below).
- BSA bovine serum albumin
- Hb human haemoglobin
- Glycation of albumin and Hb was performed as follows. For preparation of BSA-AGE, 100 mg ml- 1 of albumin was incubated with phosphate-buffered saline (PBS, 140 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium hydrogen phosphate, 1.8 mM potassium di-hydrogen phosphate, pH 7.3) containing 1 M of D-glucose-6-phosphate disodium salt hydrate (anhydrous) (g6p, ICN, Aurora, Ohio, USA) and 0.05% m/v NaN 3 , at 37°C in the dark. The solution was glycated for 70 weeks.
- PBS phosphate-buffered saline
- anhydrous g6p, ICN, Aurora, Ohio, USA
- Human Hb at 10 r ⁇ g/ml was incubated for 58 weeks at 37°C with PBS containing 1 M of g6p and 0.05% m/v of NaNe. After incubations, albumin and Hb solutions were extensively dialysed against distilled water (BSA-AGE) or against 50 mM Tris, 150 mM NaCl, pH 7.3, and, subsequently, aliquoted and stored at -20°C. Protein concentrations were determined with Advanced protein-assay reagent ADVOl (Cytoskeleton, Denver, CO, USA).
- OVA ovalbumin
- PBS Purified chicken ovalbumin
- PTC-200 thermal cycler MJ Research, Inc., Waltham, MA, USA.
- protein was heated from 30 to 85°C at a rate of 5°C/min.
- Heat-denatured OVA (DOVA) solutions were stored at -80 0 C.
- Lyophilized human amyloid- ⁇ (l-40) with E22Q mutation 'Dutch type' (Peptide facility, Dutch Cancer Institute, Amsterdam, the Netherlands) was first dissolved in 1,1,1, 6,6,6-hexafluoro-2-propanol and trifluoroacetic acid in a 1:1 volume ratio.
- Solvent was evaporated under an air stream and A ⁇ was dissolved in H2O to a final concentration of 1 mg/ml, and stored at room temperature.
- Proteins at 5 ⁇ g/ml were coated for 1 h at room temperature with agitation, in
- Microlon high-binding ELISA plates (Greiner) in 50 mM NaHCOapH 9.6. Buffer was coated as negative control. A twofold dilutions series of cell culture supernatant of HEK 293E cells over-expressing BiP was also coated to the plate for anti-FLAG-tag antibody control purposes. Plates were washed and blocked with /4*Blocking reagent (Roche). Undiluted cell culture supernatant enriched with 0.1% Tween20 was added to the wells with immobilized protein ligands and incubated for 1 h at room temperature with agitation. Medium was discarded and the plate was washed with PBS with 0.1% v/v Tween20.
- Mouse monoclonal anti-FLAG-tag antibody (Sigma, A8592, anti-FLAG M2PO conjugate) was diluted 100Ox in PBS/0.1% Tween20 and added to all wells, including those that are coated with cell culture supernatant. After a 1 h incubation at room temperature with agitation and after washing, wells were overlayed with 300Ox diluted RAMPO (DAKO Cy tomation) in PBS/0.1%
- Tween20 After 30 minutes the plate was washed and bound peroxidase was visualised with tetramethylbenzidine (TMB, #45.103.20/#45.014.01, Biosource, Nivelles, Belgium). The reaction was stopped after 5 minutes with 10% H2SO4 in H2O. Absorbance was read at 450 nm.
- Binding of IgIV was determined using an enzyme linked immunosorbent assay (ELISA) set-up. For this purpose 50 ⁇ l/well of potential ligands at indicated concentrations or coat buffer only for control and background measurement purposes, were coated overnight at 4°C, with motion, in 50 mM NaHCOa pH 9.6. Glycated albumin and Hb (BSA-AGE and Hb-AGE), control BSA and control Hb were coated at 5 ⁇ g/ml. The BSA and Hb controls were prepared freshly by dissolving lyophilized proteins at 1 mg/ml in PBS upon resuspending by pipetting, followed by a 30' period at the roller bank, at room temperature.
- ELISA enzyme linked immunosorbent assay
- the protein solutions were centrifuged for 10' at 16,000*g and diluted in coat buffer. Coat controls were performed with anti-glycated protein antibody, anti-albumin antibody, anti-Hb antibody.
- the alkaline phosphatase- conjugated anti-human Ig antibodies were controlled by coating the IgIVs and overlaying them the secondary antibodies. After coating the plates were washed twice with 50 mM Tris-HCl pH 7.3, 150 mM NaCl, 0.1% v/v Tween20, and blocked with 175 ⁇ l/well Blocking reagent (Roche Diagnostics, Almere, The Netherlands; catalogue number 11112589001), for 1 h at room temperature, with motion.
- Plates were washed twice and incubated in triplicate with indicated antibodies dilution series, plasma dilution series or controls, including binding buffer only, in the absence or presence of putative inhibitors, in binding buffer; PBS/0.1% v/v Tween20, at 50 ⁇ l/well, for 1 h at room temperature, with constant motion. After four wash cycles, secondary antibodies were added to the wells, 50 ⁇ l/well, for 45' at room temperature, with motion. RAMPO and SWARPO were used at 2000 times dilution, goat anti-human IgG antibodies were diluted 3000 times, goat anti-human IgM antibodies were diluted 1000 times. After 5 washes with wash buffer followed by two washes with PBS, binding of antibodies was assessed.
- alkaline phosphatase conjugated secondary antibodies p-nitrophenyl phosphate (600 ⁇ g/ml) in DEA buffer pH 9.8 (10% v/v diethanolamine in H 2 O, with 240 ⁇ M MgCb. ⁇ EbO, pH adjusted with HCl) was used at 100 ⁇ l/well, for ⁇ 5 minutes. The reaction was stopped by adding 50 ⁇ l/well of 2.4 M NaOH in H2O. After 5' absorbance was read at 405 nm.
- OPD peroxidase-conjugated RAMPO and SWARPO
- 50 mM citric acid/100 mM Na 2 HP ⁇ 4/0.06% v/v H2O2 pH 5 was used at 100 ⁇ l/well, for ⁇ 5 ⁇
- the reaction was stopped by adding 50 ⁇ l/well of 2 M H2SO4 in H2O. After 5' absorbance was read at 490 nm.
- Each experiment has been performed at least twice. To test whether amyloid-like crossbeta structure binding compounds and controls (see ref.
- tPA binding to amyloid -like structures is mediated by its finger domain, that is lacking in truncated K2P tPA; the kringle2 domain binds to exposed side chains of lysines and arginines).
- Binding buffer and K2P tPA serve as negative controls in these inhibition studies.
- ELISA Binding of tPA to glycated haemoglobin, misfolded ovalbumin and amyloid- ⁇
- Hb-AGE glucose-6-phosphate modified human haemoglobin
- DOVA heat-denatured ovalbumin
- amyloid- ⁇ (l- 40) E22Q 1, 3 and 9 ⁇ g/ml DOVA or AB was coated and overlayed with 0/1/3/9/27/81 nM tPA.
- ⁇ ACA ⁇ -amino caproic acid
- DMSO dimethylsulfoxide
- Hb-AGE coat at 1.25 ⁇ g/ml in Coat buffer (100 ruM NaHCO 3' pH 9.6) on a Greiner Microlon high-binding plate (catalogue number 655092), for 30 minutes at room temperature, with agitation. Coat buffer in control wells.
- tPA 50 ⁇ M Actilyse (Boehringer Ingelheim). tPA incubation at 1 nM in PBS-T buffer with 0.1% Tween20, 10 mM ⁇ -amino caproic acid and 10% (v/v) dimethylsulfoxide (DMSO) with ThT and CR concentrations of 1000/333/111/37/12.3/4.1/1.4/0 ⁇ M respectively. 6. Incubate for 30 minutes at room temperature, with agitation
- ELISA Binding of tPA to glycated haemoglobin, heat-denatured misfolded ovalbumin and amyloid- ⁇ ; influence of small compounds
- Enhancement of tPA binding was arbitrarily set to values > 100%.
- Inhibition of tPA binding to misfolded Hb-AGE was arbitrarily set to values smaller than 50%. With the chosen experimental lay-out, it can not be distinguished whether small compounds influence the interaction between tPA and Hb-AGE by binding to Hb-AGE only or by binding to tPA only or by binding to both tPA and Hb-AGE.
- Selection criteria were: a compound is assigned as an inhibitor of tPA binding when 50% or less of the signal of the control tPA binding to the ligand is observed; a compound is assigned as a stimulator of tPA binding when signals after tPA binding are increased in the presence of compounds, compared with the control tPA binding.
- amyloid- ⁇ (l-40) E22Q Dutch type (A ⁇ ) peptide aggregates with cross- ⁇ structure conformation on blood platelet aggregation was tested with washed platelets in an aggregometric assay. Freshly drawn human aspirin free blood was mixed gently with citrate buffer to avoid coagulation. Blood was spinned for 15' at 150*g at 20°C and supernatant was collected; platelet rich plasma (PRP). Buffer with 2.5% trisodium citrate, 1.5% citric acid and 2% glucose, pH 6.5 was added to a final volume ration of 1:10 (buffer- PRP).
- the pellet was resuspended in HEPES-Tyrode buffer pH 6.5.
- Prostacyclin was added to a final concentration of 10 ng/ml, and the solution was centrifuged for 15' at 330*g at 20°C, with a soft brake.
- the pellet was resuspended in HEPES-Tyrode buffer pH 7.2 in a way that the final platelet number was adjusted to 200,000/ ⁇ l. Platelets were kept at 37°C for at least 30', before use in the assays, to ensure that they were in the resting state. Aggregation of platelets was monitored in an aggregometer (Chrono-Log
- a control experiment was performed to study the influence of the red colour of hematein on the light transmission. For this, 4 ⁇ M TRAP was added at at time 1 minute to the platelets, then hematein was added after 6 minutes of aggregation. The platelets were used for not more than 4 hours after isolation to reduce variations in sensitivity amongst subsequent measurements.
- the influence of ellagic acid, another stimulator of the interaction between tPA and misfolded proteins, on AB induced platelet aggregation was assessed.
- Ellagic acid was first dissolved to 100 mg/ml in DMSO, and then further diluted to 1 mg/ml in HBS buffer.
- Immobilizer plates and Nunc Maxisorp plates Compounds were coated in 100 mM NaHCO3 pH 9.6, 50 ⁇ l/well, 1 h at room temperature with agitation. As a control, wells were coated with buffer only. After blocking of the plates, wells were overlayed with solutions of 0.1/1/10 ⁇ g/ml Hb-AGE or 10/100 ⁇ g/ml AB, in binding buffer (PBS/0.1% Tween20). After washing, binding of Hb-AGE was assessed by overlaying wells with 1 ⁇ g/ml hybridoma antibody 4B5, which binds to glycations ( 2 ), followed by RAMPO.
- Binding of AB was visualized using 50Ox diluted anti-A6 antibodies (mouse antibody beta-amyloid Clone 6F/3D #M0872, lot 00003503, DAKOCytomation; ⁇ -amyloid (H-43) SC-9129, 200 ⁇ g/ml rabbit polyclonal IgG, Santa Cruz Biotechnology) and RAMPO/SWARPO in a 1:1 ratio. Finally, wells were overlayed with OPD/H2O2 solution, and H2SO4, before absorbance readings at 490 nm.
- final concentrations tPA and tPA chromogenic substrate S- 2765 (Chromogenix, Milano, Italy) were 100 nM and 250 uM, respectively. Protease activity of tPA was followed in time by absorbance readings each minute for 2 h, at 37°C.
- tPA/plasminogen activation was measured in a kinetic assay with chromogenic plasmin substrate PNAPEP1751 (BIOPEP, Mauguio, France). Concentrations of tPA and plasminogen are 400 pM and 20 ⁇ g/ml, respectively. Heated OVA, either in PBS/1% DMSO (positive control), or in the same buffer in the presence of 1 mg/ml of the compounds, was used 40-fold diluted in the assay. Negative control was buffer without OVA.
- the human BiP gene was extended with several tags at the carboxy-terminus.
- the synthetic gene was designed in a way that at the carboxy-terminus sequences were incorporated that may aid in efficient and oriented coupling of the BiP protein molecule to (chromatography) matrices, like for example CNBr-Sepharose, NHS-Sepharose, Carboxy-link, any Ni 2+ -based affinity matrix.
- the linker sequence may be used to couple labels to the protein molecule, like for example NHS-fluorescent probe, or Universal Linkage System-biotin, which can be used for detection purposes and/or for coupling purposes using for example Streptavidin-Sepharose.
- a FLAG-tag and a His-tag is added to this carboxy-terminus.
- the original 71 kDa BiP was extended with a linker meant for matrix coupling purposes, KSKSKSMMAA, a peptide with sequence DYKDDDDK (FLAG-tag) and HHHHHH (His-tag), with a total molecular mass of 2.9 kDa.
- recombinant BiP has an apparent molecular mass of approximately 75 kDa as seen on a Western blot (not shown).
- BiP is purified using for example Ni 2+ -based affinity chromatography, anion exchange chromatography and/or gel filtration chromatography.
- BiP crossbeta structure binding ELISA with BiP
- Hb-AGE glycated haemoslobin
- Figure 4A coated native haemoslobin
- BSA native BSA
- BiP Binding of BiP occurred in the presence of 10 mM ⁇ -amino caproic acid, that prevents the interaction of the kringle2 domain (K2) of tPA and K2P-tPA with free amino groups at the exterior of the ligands.
- K2P-tPA kringle2 domain
- Hb-AGE tPA at 1 ⁇ M reduces BiP binding from 100% to 69%, whereas K2P-tPA seems to promote BiP binding to some extent.
- Hb which may comprise a fraction misfolded protein due to for example lyophilization. Similar to Hb, BiP binds to BSA-AGE and hardly to BSA.
- IgIV has affinity for misfolded proteins.
- glycated haemoglobin Hb-AGE
- ELISA glycated haemoglobin
- Figure 6A binding of IgIV to Hb-AGE is shown. Also some binding is seen to Hb that was freshly dissolved from lyophilized stock, which may result in a misfolded protein fraction, a phenomenon that is observed with lyophilized OVA (not shown).
- tPA fully inhibits the interaction of IgIV with misfolded protein ( Figure 6B), whereas K2P-tPA that lacks the finger domain that interacts with misfolded protein, does not influence the interaction.
- Amyloid-binding dye Congo red fully blocks IgIV binding, similar to tPA.
- Thioflavin T and Thioflavin S enhance the binding of IgIV ( Figure 6D, E). This activity is also seen with tPA binding to immobilized misfolded protein (not shown).
- ELISA Binding of tPA to glycated haemoglobin, misfolded ovalbumin and amyloid- ⁇
- Hb-AGE preferably are coated for subsequent competition ELISA's with 0.5 nM tPA.
- DXS ⁇ OOk is known for its ability to interact with amyloid-like moieties, its ability to denature protein and for its ability to stimulate factor XII activation in the presence of protein. See Table 7 for the sub-set of twelve compounds, used for further analyses.
- concentration series of the twelve compounds were applied to immobilized AB, Hb-AGE or misfolded OVA, followed by an overlay with a sub- optimal concentration of tPA ( Figure 13, 14, 15).
- factor XII is activated by misfolded proteins like for example amyloid-B, glycated proteins and peptides with amyloid-like conformation
- these data point to a role for protein misfolding at the surface of the established factor XII activating molecules.
- native albumin is a poor activator, as is ellagic acid when applied at low enough concentration that does not allow factor XII, prekallikrein or HMWK to denature by exposure to the ellagic acid molecules.
- albumin and ellagic acid turn into potent activators. This shows protein denaturing capacity of ellagic acid, an ability that most likely also occurs when ellagic acid is subjected to an individual.
- ellagic acid hydrate may potently compete for the binding sites with Thioflavin T, as shown when ellagic acid is added to pre-formed misfolded OVA, and/or ellagic acid can prevent formation of amyloid-like protein conformation, as shown with OVA and ellagic acid that were subjected to heat-denaturation together.
- compound 1 dehydroglaucine derivative
- 2 thaliporphine, thalicmidine
- 4 isoboldine
- compound 6 is a inhibitor of tPA binding to Hb-AGE
- 10 ellagic acid hydrate
- OVA in the presence of compound 12 (orcein) results in less tPA activity. This indicates that orcein influenced misfolding of OVA and/or that orcein competes with tPA binding.
- compound 8 haematein
- compound 8 induces further stimulation of tPA by OVA, a phenomenon that is more pronounced at 320-fold dilution.
- OVA heated in the presence of compound 10 is a stimulator of tPA activity.
- isoboldine is recognized. This is indicative of a core chemical structure with affinity for a common structural aspect in the amyloid- like misfolded proteins tested, i.e. heat-denatured ovalbumin, glycated haemoglobin and amyloid- ⁇ .
- Further refinement using a specific library comprising compounds all related to these two identified compounds 2. and 4. provides lead compounds with improved characteristics with respect to binding to amyloid-like protein conformation or to protein conformation induced by the occurrence of amyloid-like conformation. More in general, further screening of compound libraries focussed on any of the eleven identified compounds will reveal compounds related to the initially found compounds, with most likely even better binding characteristics.
- the applied screening methods showed that individual compounds can be identified from a compound library, that have not yet been known for their ability to influence misfolded protein biology.
- the method is based on screening for compounds that influence the interaction between tPA and amyloid-like misfolded proteins. So, these results demonstrate a method for selecting a compound capable of binding to a cross- ⁇ structure or in general to amyloid-like misfolded protein conformation in a protein, comprising: contacting said compound with a first protein comprising amyloid-like conformation and allowing said compound and said protein to interact; determining whether said compound at least in part binds to said amyloid-like conformation; selecting the compound that at least in part binds to said amyloid-like misfolded protein.
- the conformation recognized by the compound is either the amyloid-like conformation itself, or a conformation induced by the amyloid-like conformation, c.q. the crossbeta structure.
- the screening method is applicable for use with small compound libraries as well as with recombinant proteins and antibodies.
- chaperone BiP and human IgIV were identified as molecules with affinity for amyloid-like misfolded protein.
- Our selection methods were based on immobilized misfolded proteins as well as on misfolded proteins in solution.
- Thioflavin T and tPA binding experiments, and tPA and tPA/plasminogen activation assays provide tools for the different approaches with respect to the presentation of the misfolded protein, i.e. soluble versus immobilized on a carrier.
- Search key-words were the compound name, when known, and one or more of the key -words 'coagulation', 'amyloid', 'aggregation', 'fibril', 'misfolding', 'cell culture viability 1 , 'thrombosis', 'NF-kappaB', 'tPA', 'factor XIF, 'Alzheimer', 'amyloidosis', 'protocol', 'method', 'review'.
- the search was completed Spring 2006. A brief summary is given in Table 11.
- Figure 1 Monoclonal antibodies elicited against amyloid A ⁇ , chicken serum amyloid A and glycated haemoglobin bind to various polypeptide aggregates with cross- ⁇ structure conformation, but without amino acid homology.
- Hybridoma cell culture supernatants are brought into wells of ELISA plates with coated buffer (H2O, 'no coat Greiner') or with immobilized antigens with cross- ⁇ structure conformation, used for immunization (A ⁇ (l-40) E22Q and Hb- AGE), and used as unrelated ligand for putative anti-cross- ⁇ structure- dependent antibodies (amyloid human ⁇ -globulins and amyloid FP13 K157G).
- Freshly dissolved and centrifuged A ⁇ , FP13 K157G, control Hb and ⁇ -globulins were immobilized as negative control, as well as PBS ('no coat Exiqon'), as shown for clone 7Hl.
- Clone 7Hl was tested in single wells on each antigen and on non-amyloid controls, whereas clones 2E2, 4F4, 7H2, 7H9 and 8F2 were tested in duplicate, in pre -blocked wells, on amyloid antigens only.
- G-J. Monoclonal 7H2 shows selectivity for human ⁇ -globulins with cross- ⁇ structure conformation.
- ELISA with a dilution series of hybridoma clone 7H2H2 and immobilized amyloid ⁇ -globulins, acid-denatured ⁇ -globulins, base-denatured ⁇ -globulins and freshly prepared native ⁇ -globulins.
- Cell culture medium with 7H2H2 IgM was used undiluted and diluted 2/4/8/16/32/64/128/256/512/1024 times.
- Undiluted cell culture medium with 7H2 subclones was tested on immobilized antigens A ⁇ and Hb-AGE, as well as on unrelated amyloid-like structure conformations amyloid ⁇ -globulins and FP13 K157G.
- Figure 2 Binding of factor XII and tPA to ⁇ 2-glycoprotein I and binding of anti-Jp2GPI auto-antibodies to recombinant ⁇ 2GPI.
- Recombinant ⁇ 2GPI binds with a ko of 0.9 ⁇ g ml" 1 (20 nM) to immobilized factor XII.
- D Western blot incubated with anti-human factor XII antibody.
- the ⁇ 2GPI was purified either from fresh human plasma or from plasma that was frozen at -2O 0 C and subsequently thawed before purification on a 62GPI affinity column. Eluted fractions are analyzed on Western blot after SDS-PA electrophoresis. When comparing lanes 2-3 with 4-5, it is shown that freezing-thawing of plasma results in co-purification of factor XII together with the ⁇ 2GPI.
- the molecular mass of factor XII is 80 kDa.
- B2GPI contacted to CL binds tPA to a higher extent than 62GPI contacted to the ELISA plate directly.
- K2P-tPA does not bind to B 2 GPI.
- TPA does not bind to immobilized CL.
- H Transmission electron microscopy images of 400 ⁇ g ml" 1 purified plasma ⁇ 2GPI alone (1) or contacted with 100 ⁇ M CL (2, 3) and of 400 ⁇ g ml 1 purified recombinant ⁇ 2GPI (4).
- Positive control is 100 ⁇ g ml" 1 amyloid ⁇ -globulins.
- Negative control is buffer (H2O).
- E X-ray diffraction image showing the typical 4.7 A reflection seen in amyloid-like structures of varying origin.
- the diffraction pattern belongs to FP6 with amyloid structure type 1.
- F X-ray diffraction pattern of FP6 that adopted a fibrillar conformation with amyloid-like properties. Adjacent ⁇ -sheets are shifted 2.35 ⁇ and as a result the 4.7 A peak, typical in many amyloid structures, is quenched completely.
- G Structural model based on the X-ray fiber diffraction analyzes of 37°C-incubated FP6 and freshly dissolved FP6, showing the ⁇ -sheet stacking within the cross- ⁇ structure.
- Alternating layers are supposed, harbouring either the hydrophobic isoleucine side-chains (I), or the charged lysine (K), arginine (R) and aspartate (D) residues.
- H In the crystal structure of the 37 0 C incubated FP6 (structure 1), ⁇ - sheets in consecutive layers are shifted over half the unit cell length in the direction of the 4.7 A hydrogen bonds perpendicular to the peptide bonds (fiber axis). In contrast, in the crystal structure of the freshly dissolved FP6 (structure 2), ⁇ -strands in consecutive ⁇ -sheet layers are oriented on top of each other.
- I Size exclusion chromatography run with freshly dissolved FP6.
- Figure 4 Binding of recombinant human BiP to crossbeta structure comprising proteins.
- BiP binds to glycated haemoglobin (Hb-AGE) and to a lesser extent to freshly dissolved lyophilized haemoglobin.
- B. BiP binds to glycated albumin (BSA-AGE) and not to native BSA.
- BSA-AGE glycated albumin
- Figure 5 Binding of BiP to protein-AGE adducts with crossbeta structure is inhibited by tPA.
- Binding of over-expressed recombinant human BiP in cell culture medium to immobilized Hb-AGE and BSA-AGE is inhibited by tPA and not by K2P-tPA that lacks the crossbeta structure binding finger domain, as determined in an ELISA set-up. Binding of BiP in threefold diluted cell culture medium is set to 100%.
- ELISA set-ups the binding of human IgIV for therapeutical usage was assessed with immobilized glycated proteins.
- a concentration series of coated Hb-AGE is overlayed with a concentration series of tPA in PBS/0.1% Tween20/10 mM ⁇ ACA/10% DMSO.
- OVA ovalbumin
- a ⁇ amyloid- ⁇
- FIG. 9 Influence of small compounds on tPA binding to Hb-AGE. Small compounds were co-incubated with 0.5 nM tPA. Inhibition or stimulation of tPA binding (in %) was determined relative to binding of tPA.
- [Hb-AGE] is 1.25 ⁇ g/nl.
- [ThT] is 1 mM (positive control for stimulated tPA binding).
- [Congo red] is 0.5 mM (positive control for inhibited tPA binding). Criteria for stimulated binding by a compound: net absorbance value >100% compared to tPA binding without compound (at least 1.5-fold stimulation). Criteria for inhibited tPA binding by a compound: absorbance value ⁇ 50% compared to tPA (at least 50% inhibition).
- Figure 10 Compounds that influence interaction of tPA with misfolded proteins Hb-AGE, heat-denatured misfolded ovalbumin and amyloid- ⁇ .
- Figure 16 Activation of factor XII and prekallikrein by ellagic acid is dependent on the presence of protein.
- the upper figure depicts the enhancement of Thioflavin T fluorescence when pre-formed misfolded ovalbumin is mixed with separately heated small compounds (see legend to the figure).
- the lower figure depicts the enhancement of Thioflavin T fluorescence when ovalbumin and small compounds are first mixed and then heated.
- Figure 19 Blood platelet aggregation under influence of amyloid- ⁇ , haematein and ellagic acid.
- Figure 20 Influence of ovalbumin heated in the presence of small compounds, on tPA serine protease activity.
- Ovalbumin heated in buffer ('misfolded OVA') or in the presence of small compounds (indicated with the compound number according to Table 9 and its name) as indicated, was tested for its influence on the tPA serine protease activity.
- Stock solutions of 1 mg/ml ovalbumin in buffer or in the presence of 1 mg/ml compound were diluted in the assay as indicated.
- tPA activity was determined using chromogenic substrate S-2765.
- FIG 21 Influence of ovalbumin heated in the presence of small compounds, on formation of plasmin. Plasmin substrate PNAPEP1751 conversion was followed in time with misfolded ovalbumin ('misfolded OVA) or with heated mixtures of ovalbumin and the indicated small compounds (indicated with the compound number and name, see Table 9).
- plasmin activity was assayed in a chromogenic assay.
- Compounds were included in the assay, or control buffer (80-fold or 160- fold diluted PBS/1% DMSO, compound buffer).
- the compound number and name indicate assays with misfolded ovalbumin and the compound.
- Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 12, 1833-1839 (2002).
- Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb. Haemost. 76, 916-924 (1996).
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006267176A AU2006267176A1 (en) | 2005-07-13 | 2006-07-13 | Cross-beta structure binding compounds |
AT06783842T ATE554394T1 (en) | 2005-07-13 | 2006-07-13 | CROSS BETA STRUCTURE BINDING CONNECTIONS |
US11/995,497 US8067187B2 (en) | 2005-07-13 | 2006-07-13 | Cross-β structure binding compounds |
EP06783842A EP1910844B1 (en) | 2005-07-13 | 2006-07-13 | Cross-beta structure binding compounds |
CA002615028A CA2615028A1 (en) | 2005-07-13 | 2006-07-13 | Cross-.beta. structure binding compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05076613 | 2005-07-13 | ||
EP05076613.8 | 2005-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007008072A2 true WO2007008072A2 (en) | 2007-01-18 |
WO2007008072A3 WO2007008072A3 (en) | 2007-05-18 |
Family
ID=34938373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2006/000364 WO2007008072A2 (en) | 2005-07-13 | 2006-07-13 | CROSS-ß STRUCTURE BINDING COMPOUNDS |
Country Status (7)
Country | Link |
---|---|
US (1) | US8067187B2 (en) |
EP (2) | EP1910844B1 (en) |
AT (1) | ATE554394T1 (en) |
AU (1) | AU2006267176A1 (en) |
CA (1) | CA2615028A1 (en) |
WO (1) | WO2007008072A2 (en) |
ZA (1) | ZA200800862B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007094668A1 (en) * | 2006-02-16 | 2007-08-23 | Crossbeta Biosciences B.V. | Affinity regions |
WO2007108675A1 (en) * | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
US8067187B2 (en) | 2005-07-13 | 2011-11-29 | Crossbeta Biosciences B.V. | Cross-β structure binding compounds |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
WO2007008073A2 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF |
JP2009501215A (en) * | 2005-07-13 | 2009-01-15 | クロスベータ、バイオサイエンセス、ベスローテン、フェンノートシャップ | Adjuvant formation by cross β structure |
EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
US20150291547A1 (en) * | 2011-09-26 | 2015-10-15 | Nanyang Polytechnic | Small molecules for extending the well being of cells and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US5801200A (en) * | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5733524A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5700447A (en) * | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5733933A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
DE3682891D1 (en) | 1986-02-17 | 1992-01-23 | Stichting Centraal Lab | TISSUE PLASMINOGEN ACTIVATOR MUTANT, THEREFORE ENCODING RECOMBINANT GENETIC INFORMATION AND METHOD FOR THE PRODUCTION OF THESE MUTANTS, THEIR USE AND PHARMACEUTICAL COMPOSITIONS. |
EP0319144A1 (en) * | 1987-11-06 | 1989-06-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Adsorbent of beta 2-microglobulin |
US5216127A (en) * | 1987-11-20 | 1993-06-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for serum amyloid protein |
DE3853219T2 (en) | 1987-11-20 | 1995-06-29 | Kanegafuchi Chemical Ind | Method of removing serum amyloid protein. |
US5151082A (en) | 1988-08-05 | 1992-09-29 | Heathdyne, Inc. | Apparatus and method for kidney dialysis using plasma in lieu of blood |
CA1335361C (en) * | 1989-05-24 | 1995-04-25 | Andrei Z. Budzynski | Thrombus-targeted complexes of plasminogen activator and fibrin fragments |
US5180615A (en) * | 1989-12-13 | 1993-01-19 | W.R. Grace & Co.-Conn. | Metallized bag for static protection of electronic components |
US5591431A (en) * | 1990-03-09 | 1997-01-07 | G.D. Searle & Co. | Enhancement of clot lysis |
US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US5650418A (en) * | 1990-06-04 | 1997-07-22 | Therapy 2000 | Therapeutic lysine salt composition and method of use |
US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
US5230996A (en) * | 1990-06-04 | 1993-07-27 | Therapy 2000 | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation |
US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
SE468881B (en) | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | APPLICATION OF CERTAIN PHARMACEUTICALS FOR THE PREPARATION OF MEDICINAL PRODUCTS FOR TREATMENT OF ENDOTOXIN-INDEXED EFFECTS AND THE PREPARATION OF ENDOTOXINES FROM MISCELLANEOUS SOLUTIONS |
US5221628A (en) * | 1991-03-19 | 1993-06-22 | Northwestern University | Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component |
US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
US5491129A (en) * | 1992-07-30 | 1996-02-13 | Yeda Research And Development Co. Ltd. | Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them |
US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
DE4242736A1 (en) * | 1992-12-17 | 1994-06-23 | Behringwerke Ag | Synthetic peptides, antibodies against them and their use |
US5955343A (en) * | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5560418A (en) * | 1993-04-02 | 1996-10-01 | Advantage Office Systems, L.L.C. | Attachment bar for partition panel |
US5449663A (en) * | 1993-06-11 | 1995-09-12 | Bicher; Haim I. | Antineoplastic compositions |
ATE249234T1 (en) | 1993-12-17 | 2003-09-15 | Mochida Pharm Co Ltd | PREPARATION CONTAINING SOLUBLE THROMBOMODULIN |
US6410598B1 (en) * | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
CA2182731A1 (en) * | 1994-02-03 | 1995-08-10 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
KR0163563B1 (en) * | 1994-03-23 | 1998-12-01 | 김종인 | Topical drug in combination for treatment of skin lesions |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US6136548A (en) * | 1994-11-22 | 2000-10-24 | Rutgers, The State University Of New Jersey | Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US5888774A (en) | 1994-12-19 | 1999-03-30 | Cangene Corporation | Recombinant DNA molecules and expression vectors for erythropoietin |
US5854215A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
US5817626A (en) * | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
ES2175083T3 (en) * | 1995-03-14 | 2002-11-16 | Praecis Pharm Inc | AMULOID AGGREGATION MODULATORS. |
US5948763A (en) | 1995-06-07 | 1999-09-07 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
US6436969B1 (en) * | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
JPH11513490A (en) * | 1995-10-02 | 1999-11-16 | カトット,モハメド,ダブリュ. | Biologically active polymer |
US5985242A (en) * | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US6310046B1 (en) * | 1995-11-17 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Sequestrin of Plasmodium falciparum |
AU1529297A (en) * | 1996-01-24 | 1997-08-20 | Warner-Lambert Company | Method of imaging amyloid deposits |
US5785187A (en) * | 1996-04-29 | 1998-07-28 | Lipman; Daniel | Mechandising display assembly |
US6034211A (en) * | 1996-06-03 | 2000-03-07 | Kelly; Jeffery W. | β-sheet nucleating peptidomimetics |
US6929807B1 (en) * | 1996-08-09 | 2005-08-16 | Mannatech, Inc. | Compositions of plant carbohydrates as dietary supplements |
US6689275B1 (en) * | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
US6372473B1 (en) * | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
US20020122807A1 (en) * | 1998-07-07 | 2002-09-05 | Dan Michael D. | Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
DE19735902A1 (en) | 1997-08-19 | 1999-02-25 | Imtec Immundiagnostika Gmbh | New selective adsorbent carrying peptide(s) that mimic complement C1q |
WO1999009999A1 (en) * | 1997-08-28 | 1999-03-04 | University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
EP1032403B1 (en) * | 1997-10-24 | 2012-05-02 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
JP4037525B2 (en) | 1998-03-25 | 2008-01-23 | 生化学工業株式会社 | New antibacterial peptide |
US7041287B2 (en) * | 1998-05-21 | 2006-05-09 | Trustees Of The University Of Pennsylvania | Compositions and methods for selective dissolution of nascent intravascular blood clots |
US6416963B1 (en) | 1998-08-12 | 2002-07-09 | New York Blood Center | Cleaved fragments of fibrinogen |
WO2000018398A1 (en) | 1998-09-25 | 2000-04-06 | Sunol Molecular Corporation | Pharmaceutically active compounds and methods of use thereof |
IN190822B (en) | 1998-12-24 | 2003-08-23 | Council Scient Ind Res | |
US6242473B1 (en) | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
US6161547A (en) | 1999-01-15 | 2000-12-19 | Coaxia, Inc. | Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use |
JP4579422B2 (en) | 1999-04-30 | 2010-11-10 | 明 松本 | Human brain carboxypeptidase B |
AT500670A1 (en) | 1999-05-19 | 2006-02-15 | Bio & Bio Licensing Sa | DRUGS FOR LOCAL APPLICATION |
GB9917725D0 (en) | 1999-07-28 | 1999-09-29 | Medical Res Council | Peptides |
WO2001012598A2 (en) | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
US20040013647A1 (en) * | 1999-09-03 | 2004-01-22 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating a plaque-forming disease |
ATE239741T1 (en) | 1999-09-14 | 2003-05-15 | Meiji Seika Kaisha | PHOSPHONIC ACID DERIVATIVES FOR INHIBITING CARBOXYPEPTIDASE B |
US6399314B1 (en) * | 1999-12-29 | 2002-06-04 | American Cyanamid Company | Methods of detection of amyloidogenic proteins |
EP1252181B1 (en) | 2000-01-20 | 2006-01-18 | Regents Of The University Of Minnesota | Peptides with antibacterial activity |
AU3173301A (en) | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
CN1279971C (en) | 2000-02-21 | 2006-10-18 | 法麦克萨有限公司 | Novel method for down-regulation of amyloid |
AU783144B2 (en) * | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
EP1130031A1 (en) * | 2000-02-25 | 2001-09-05 | Universitair Medisch Centrum Utrecht | Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
AU2001247667A1 (en) * | 2000-03-21 | 2001-10-03 | Research Foundation Of State University Of New York | Adsorption of polyampholytes to charged surfaces and assays incorporating same |
PL215711B1 (en) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
EP1186299A1 (en) * | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
DK1219300T3 (en) | 2000-12-28 | 2007-03-05 | Biomay Prod & Handel | Treatment of allergies |
EP1383885A4 (en) | 2001-04-04 | 2005-11-30 | American Diagnostica Inc | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof |
JP4235544B2 (en) | 2001-05-31 | 2009-03-11 | アドライフ インコーポレーティッド | Defect folding protein sensor method |
US6960465B1 (en) * | 2001-06-27 | 2005-11-01 | Northwestern University | Increased cell resistance to toxic organic substances |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
EP1414491A4 (en) * | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | Methods of inhibiting amyloid toxicity |
JP2003024080A (en) * | 2001-07-19 | 2003-01-28 | Univ Tokyo | Protein inducing p53-dependent apoptosis and method for screening apoptosis controlling agent |
GB0202275D0 (en) | 2002-01-31 | 2002-03-20 | Hansa Medica Ab | Peptide |
EP1820806A1 (en) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinity regions |
NZ535276A (en) | 2002-02-28 | 2008-04-30 | Microsens Biophage Ltd | Binding of pathological forms of prion proteins |
KR100518152B1 (en) * | 2002-05-09 | 2005-09-29 | 메디제네스(주) | A Pharmaceutical Composition for Treatment of Wounds Containing Blood Plasma or Serum |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
US20050142611A1 (en) * | 2002-09-30 | 2005-06-30 | Auburn University | Method of isolation and self-assembly of small protein particles from blood and other biological materials |
US7470667B2 (en) * | 2002-12-05 | 2008-12-30 | Medgenn (Hong Kong) Ltd | Methods of treating cancer using a modified endostatin protein |
EP1449536A1 (en) | 2003-02-14 | 2004-08-25 | Prionics AG | Prion proteins (PrP) as therapeutic agents for the treatment of AP-1 associated diseases |
WO2004073651A2 (en) * | 2003-02-18 | 2004-09-02 | The Ohio State University Research Foundation | Identifying inhibitors of intracellular protein fibrillization |
DK2520654T3 (en) | 2003-08-26 | 2017-05-01 | Univ Colorado Regents | Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections |
ATE462716T1 (en) | 2003-10-24 | 2010-04-15 | Amgen Inc | METHOD FOR THE PURIFICATION OF PROTEINS IN A FLOW FRACTION FROM CHROMATOGRAPHY WITH HYDROPHOBIC INTERACTIONS |
WO2006006172A2 (en) | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
JP2008531553A (en) * | 2005-02-25 | 2008-08-14 | メディジーンズ カンパニー リミテッド | Pharmaceutical composition for the treatment of Avellino corneal dystrophy comprising plasma or serum |
EP1704867A1 (en) * | 2005-03-18 | 2006-09-27 | Crossbeta Biosciences B.V. | Cross-beta structures on microbial organisms |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
WO2007008073A2 (en) | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF |
JP2009501215A (en) * | 2005-07-13 | 2009-01-15 | クロスベータ、バイオサイエンセス、ベスローテン、フェンノートシャップ | Adjuvant formation by cross β structure |
WO2007008072A2 (en) | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | CROSS-ß STRUCTURE BINDING COMPOUNDS |
US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
WO2007018400A1 (en) | 2005-08-11 | 2007-02-15 | Medigenes Co., Ltd | Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum |
US8543424B2 (en) * | 2005-12-30 | 2013-09-24 | Darryl Mark Hunsaker | Vehicle insurance status display system |
EP2007800A1 (en) | 2006-03-17 | 2008-12-31 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
-
2006
- 2006-07-13 WO PCT/NL2006/000364 patent/WO2007008072A2/en active Application Filing
- 2006-07-13 AU AU2006267176A patent/AU2006267176A1/en not_active Abandoned
- 2006-07-13 EP EP06783842A patent/EP1910844B1/en not_active Not-in-force
- 2006-07-13 CA CA002615028A patent/CA2615028A1/en not_active Abandoned
- 2006-07-13 AT AT06783842T patent/ATE554394T1/en active
- 2006-07-13 US US11/995,497 patent/US8067187B2/en not_active Expired - Fee Related
- 2006-07-13 EP EP11153446A patent/EP2386861A3/en not_active Withdrawn
-
2008
- 2008-01-28 ZA ZA200800862A patent/ZA200800862B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
Non-Patent Citations (3)
Title |
---|
BOUMA BAREND ET AL: "Glycation induces formation of amyloid cross-beta structure in albumin" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 43, 24 October 2003 (2003-10-24), pages 41810-41819, XP002343361 ISSN: 0021-9258 * |
CARDOSO I ET AL: "APROTININ BINDING TO AMYLOID FIBRILS" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 267, no. 8, April 2000 (2000-04), pages 2307-2311, XP001128718 ISSN: 0014-2956 * |
O'NUALLAIN BRIAN ET AL: "Conformational Abs recognizing a generic amyloid fibril epitope" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 3, 5 February 2002 (2002-02-05), pages 1485-1490, XP002211263 ISSN: 0027-8424 cited in the application * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067187B2 (en) | 2005-07-13 | 2011-11-29 | Crossbeta Biosciences B.V. | Cross-β structure binding compounds |
WO2007094668A1 (en) * | 2006-02-16 | 2007-08-23 | Crossbeta Biosciences B.V. | Affinity regions |
WO2007108675A1 (en) * | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
Also Published As
Publication number | Publication date |
---|---|
AU2006267176A1 (en) | 2007-01-18 |
EP1910844B1 (en) | 2012-04-18 |
EP2386861A3 (en) | 2012-07-18 |
ZA200800862B (en) | 2009-01-28 |
WO2007008072A3 (en) | 2007-05-18 |
EP2386861A2 (en) | 2011-11-16 |
US20080267948A1 (en) | 2008-10-30 |
ATE554394T1 (en) | 2012-05-15 |
CA2615028A1 (en) | 2007-01-18 |
US8067187B2 (en) | 2011-11-29 |
EP1910844A2 (en) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1910844B1 (en) | Cross-beta structure binding compounds | |
US8158585B2 (en) | Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity | |
CA2601880A1 (en) | Method for interfering with blood coagulation by modulating cross-beta structures fibril formation | |
US20090155254A1 (en) | Affinity Regions | |
US20080207488A1 (en) | Method for Detecting Peptides Comprising a Cross-B Structure | |
US20100015126A1 (en) | Methods of Binding of Cross-Beta Structures By Chaperones | |
WO2017027611A2 (en) | Biomarkers of methylglyoxal and related methods thereof | |
US20080249606A1 (en) | Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof | |
US20090202980A1 (en) | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation | |
AU2006267175A1 (en) | Method for detecting peptides comprising a cross-beta structure | |
BR112020018868A2 (en) | antibody-based methods to detect and treat alzheimer's disease | |
Zhang et al. | A disulfide-stabilized Aβ that forms dimers but does not form fibrils | |
Wiegand | Molecular epitope and affinity determination of protein-protein interactions by a combination of biosensor and mass spectrometric methods | |
US20210139568A1 (en) | Antibody-based methods of detecting and treating alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2615028 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006267176 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 565336 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006783842 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006267176 Country of ref document: AU Date of ref document: 20060713 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11995497 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06783842 Country of ref document: EP Kind code of ref document: A2 |